


**CUMULATIVE
SUPPLEMENT 03
March 2009**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Cumulative Supplement 3

March 2009

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	v
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	vii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**CUMULATIVE SUPPLEMENT 3
March 2009**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not

previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2008</u>	<u>MAR 2009</u>	<u>JUN 2009</u>	<u>SEPT 2009</u>
DRUG PRODUCTS LISTED	12751	12910		
SINGLE SOURCE	2433	2449		
	(19.1%)	(19.0%)		
MULTISOURCE	10229	10372		
	(80.2%)	(80.3%)		
THERAPEUTICALLY EQUIVALENT	10072	10216		
	(79.0%)	(79.1%)		
NOT THERAPEUTICALLY EQUIVALENT	157	156		
	(1.2%)	(1.2%)		
EXCEPTIONS ¹	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES APPROVED	15	5		
NUMBER OF APPLICANTS	719	724		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 28TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

1-1

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	SANDOZ	300MG;30MG	N81250 001	Jul 16, 1992	Mar	DISC
>A>		@	300MG;30MG	N81250 001	Jul 16, 1992	Mar	DISC
>D>	AA		300MG;60MG	N81249 001	Jul 16, 1992	Mar	DISC
>A>		@	300MG;60MG	N81249 001	Jul 16, 1992	Mar	DISC
			TYLENOL W/ CODEINE NO. 4				
>D>		@ ORTHO MCNEIL JANSSEN	300MG;60MG	N85055 004		Mar	CMFD
>A>	AA		300MG;60MG	N85055 004		Mar	CMFD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT	500MG;5MG	N89006 001	Aug 09, 1985	Feb	CTNA
----------------	-----------	------------	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AA	SANDOZ	650MG;65MG	N89959 001	Jul 18, 1989	Mar	DISC
>A>		@	650MG;65MG	N89959 001	Jul 18, 1989	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	SANDOZ	650MG;100MG	N70443 001	Jan 23, 1986	Mar	DISC
>A>		@	650MG;100MG	N70443 001	Jan 23, 1986	Mar	DISC

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

@ ARMSTRONG PHARMS	0.09MG/INH	N72273 001	Aug 14, 1996	Jan	DISC
--------------------	------------	------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	HOLOPACK INTL	EQ 0.083% BASE	N77839 001	Dec 16, 2008	Jan	CAHN
----	---------------	----------------	------------	--------------	-----	------

TABLET; ORAL

ALBUTEROL SULFATE

>D>	AB	SANDOZ	EQ 2MG BASE	N72151 001	Dec 05, 1989	Mar	DISC
>A>		@	EQ 2MG BASE	N72151 001	Dec 05, 1989	Mar	DISC
>D>	AB		EQ 4MG BASE	N72152 001	Dec 05, 1989	Mar	DISC
>A>		@	EQ 4MG BASE	N72152 001	Dec 05, 1989	Mar	DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>D>	AB	SANDOZ	100MG	N70268 001	Dec 31, 1985	Mar	DISC
>A>		@	100MG	N70268 001	Dec 31, 1985	Mar	DISC
>D>	AB		300MG	N70269 001	Dec 31, 1985	Mar	DISC
>A>		@	300MG	N70269 001	Dec 31, 1985	Mar	DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	+	PAR PHARM	5MG	N70346	001	Jan 22, 1986	Jan	CTEC
AB		SIGMAPHARM LABS LLC	5MG	N79133	001	Jan 30, 2009	Jan	NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	SANDOZ	EQ 5MG ANHYDROUS;50MG	N73357	001	Nov 27, 1991	Mar	DISC
>A>		@	EQ 5MG ANHYDROUS;50MG	N73357	001	Nov 27, 1991	Mar	DISC

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

		XANODYNE PHARM	1GM	N15197	002	Jun 24, 2004	Jan	NEWA
--	--	----------------	-----	--------	-----	--------------	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	GLENMARK GENERICS	EQ 2.5MG BASE	N78552	001	Apr 08, 2009	Mar	NEWA
>A>	AB		EQ 5MG BASE	N78552	002	Apr 08, 2009	Mar	NEWA
>A>	AB		EQ 10MG BASE	N78552	003	Apr 08, 2009	Mar	NEWA
	AB	SYNTHON PHARMS	EQ 2.5MG BASE	N77080	001	Jun 27, 2007	Jan	CAHN
	AB		EQ 5MG BASE	N77080	002	Jun 27, 2007	Jan	CAHN
	AB		EQ 10MG BASE	N77080	003	Jun 27, 2007	Jan	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		APOTEX	250MG;EQ 125MG BASE	N65333	001	Feb 24, 2009	Feb	NEWA
AB			500MG;EQ 125MG BASE	N65333	002	Feb 24, 2009	Feb	NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT		AKORN INC	EQ 0.5% BASE	N77764	001	Mar 12, 2009	Feb	NEWA
AT	+	ALCON	EQ 0.5% BASE	N20258	001	Jul 30, 1993	Feb	CFTG

ARMODAFINIL

TABLET; ORAL

NUVIGIL

>D>		@ CEPHALON	100MG	N21875	002	Jun 15, 2007	Mar	CMFD
>A>			100MG	N21875	002	Mar 26, 2009	Mar	CMFD
>A>			200MG	N21875	005	Mar 26, 2009	Mar	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AB	SANDOZ	325MG;50MG;40MG	N86398	002	Apr 06, 1984	Mar	DISC
>A>		@	325MG;50MG;40MG	N86398	002	Apr 06, 1984	Mar	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ SOLCO HLTHCARE 385MG;30MG;25MG N75141 001 May 29, 1998 Jan CAHN

ORPHENGESIC FORTE

@ SOLCO HLTHCARE 770MG;60MG;50MG N75141 002 May 29, 1998 Jan CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@ HOSPIRA 10MG/ML N74740 001 Mar 28, 1997 Jan DISC

ATRACURIUM BESYLATE PRESERVATIVE FREE

@ HOSPIRA 10MG/ML N74741 001 Mar 28, 1997 Jan DISC

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

>A> + CELGENE 100MG/VIAL N50794 001 May 19, 2004 Mar CAHN

>D> + PHARMION LLC 100MG/VIAL N50794 001 May 19, 2004 Mar CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>A> AP SAGENT STRIDES EQ 500MG BASE/VIAL N65506 001 Mar 24, 2009 Mar NEWA

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

>A> + LEO PHARM 0.064%;0.005% N21852 001 Jan 09, 2006 Mar CAHN

>D> + LEO PHARM PRODS 0.064%;0.005% N21852 001 Jan 09, 2006 Mar CAHN

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

>A> AN APOTEX 0.25MG/2ML N78202 001 Mar 30, 2009 Mar NEWA

>A> AN 0.5MG/2ML N78202 002 Mar 30, 2009 Mar NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A> AB1 WATSON LABS 100MG N79095 001 Mar 24, 2009 Mar NEWA

>A> AB2 150MG N79094 001 Mar 24, 2009 Mar NEWA

>A> AB1 150MG N79095 002 Mar 24, 2009 Mar NEWA

>A> AB1 200MG N79095 003 Mar 24, 2009 Mar NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB + BRISTOL MYERS SQUIBB 15MG N18731 003 Apr 22, 1996 Feb CRLD

@ 30MG N18731 004 Apr 22, 1996 Feb DISC

BUSPIRONE HYDROCHLORIDE

AB DR REDDYS LABS LTD 5MG N78246 001 Feb 27, 2009 Feb NEWA

AB 10MG N78246 002 Feb 27, 2009 Feb NEWA

AB 15MG N78246 003 Feb 27, 2009 Feb NEWA

AB 30MG N78246 004 Feb 27, 2009 Feb NEWA

TABLET; ORALBUSPIRONE HYDROCHLORIDE

>D>	AB	SANDOZ	5MG	N75413 001	Mar 19, 2002	Mar	DISC
>A>		@	5MG	N75413 001	Mar 19, 2002	Mar	DISC
>D>	AB		10MG	N75413 002	Mar 19, 2002	Mar	DISC
>A>		@	10MG	N75413 002	Mar 19, 2002	Mar	DISC
>D>	AB		15MG	N75413 003	Mar 19, 2002	Mar	DISC
>A>		@	15MG	N75413 003	Mar 19, 2002	Mar	DISC

CALCITRIOLCAPSULE; ORALROCALTROL

>D>	AB	FONTUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
>D>	AB	+	0.5UGM	N18044 002		Mar	CAHN
>A>	AB	VALIDUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
>A>	AB	+	0.5UGM	N18044 002		Mar	CAHN

OINTMENT; TOPICALVECTICAL

	+	GALDERMA LABS LP	3UGM/GM	N22087 001	Jan 23, 2009	Jan	NEWA
--	---	------------------	---------	------------	--------------	-----	------

SOLUTION; ORALROCALTROL

>D>	AA	+	FONTUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN
>A>	AA	+	VALIDUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN

CARBAMAZEPINETABLET, CHEWABLE; ORALCARBAMAZEPINE

	AB	TORRENT PHARMS	100MG	N75712 001	Jul 05, 2001	Jan	CAHN
--	----	----------------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORALCARBAMAZEPINE

>A>	AB	TARO	100MG	N78115 001	Mar 31, 2009	Mar	NEWA
>A>	AB		200MG	N78115 002	Mar 31, 2009	Mar	NEWA
>A>	AB		400MG	N78115 003	Mar 31, 2009	Mar	NEWA

TEGRETOL-XR

>D>		NOVARTIS	100MG	N20234 001	Mar 25, 1996	Mar	CFTG
>A>	AB		100MG	N20234 001	Mar 25, 1996	Mar	CFTG
>D>			200MG	N20234 002	Mar 25, 1996	Mar	CFTG
>A>	AB		200MG	N20234 002	Mar 25, 1996	Mar	CFTG
>D>		+	400MG	N20234 003	Mar 25, 1996	Mar	CFTG
>A>	AB	+	400MG	N20234 003	Mar 25, 1996	Mar	CFTG

>D> CARBENICILLIN INDANYL SODIUM>D> TABLET; ORAL>D> GEOCILLIN

>D>		+	PFIZER	EQ 382MG BASE	N50435 001		Mar	DISC
>A>		@		EQ 382MG BASE	N50435 001		Mar	DISC

CARBIDOPA; LEVODOPATABLET; ORALCARBIDOPA AND LEVODOPA

>D>	AB	SANDOZ	10MG;100MG	N73586 001	Jun 29, 1995	Mar	DISC
>A>		@	10MG;100MG	N73586 001	Jun 29, 1995	Mar	DISC
>D>	AB		25MG;100MG	N73587 001	Jun 29, 1995	Mar	DISC
>A>		@	25MG;100MG	N73587 001	Jun 29, 1995	Mar	DISC
>D>	AB		25MG;250MG	N73620 001	Jun 29, 1995	Mar	DISC
>A>		@	25MG;250MG	N73620 001	Jun 29, 1995	Mar	DISC

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Feb	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Feb	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>D>	AA	SANDOZ	350MG	N81025 001	Apr 13, 1989	Mar	DISC
>A>		@	350MG	N81025 001	Apr 13, 1989	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>A>	AP	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280 001	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65280 002	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL	N65295 001	Mar 18, 2009	Mar	NEWA
>A>	AP		EQ 20GM BASE/VIAL	N65296 001	Mar 18, 2009	Mar	NEWA
>D>	AP	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N64033 001	Oct 31, 1993	Mar	DISC
>A>		@	EQ 1GM BASE/VIAL	N64033 001	Oct 31, 1993	Mar	DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

>D>	AP	SANDOZ	EQ 2GM BASE/VIAL	N65169 004	May 09, 2005	Mar	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	N65169 004	May 09, 2005	Mar	CRLD

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

>D>	AB	SANDOZ	100MG	N88725 001	Aug 31, 1984	Mar	DISC
>A>		@	100MG	N88725 001	Aug 31, 1984	Mar	DISC
>D>	AB		250MG	N88726 001	Aug 31, 1984	Mar	DISC
>A>		@	250MG	N88726 001	Aug 31, 1984	Mar	DISC

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>D>	AA	SANDOZ	250MG	N89852 001	May 04, 1988	Mar	DISC
>A>		@	250MG	N89852 001	May 04, 1988	Mar	DISC
>D>	AA		500MG	N89853 001	May 04, 1988	Mar	DISC
>A>		@	500MG	N89853 001	May 04, 1988	Mar	DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

ABBOTT LABS

+

			EQ 45MG FENOFIBRIC ACID	N22224 001	Dec 15, 2008	Jan	CTNA
			EQ 135MG FENOFIBRIC ACID	N22224 002	Dec 15, 2008	Jan	CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

>D>		@ ABBOTT	4,000 UNITS/VIAL	N18663 002	Aug 21, 1984	Mar	CAHN
-----	--	----------	------------------	------------	--------------	-----	------

INJECTABLE; INJECTION

CHYMODIACTIN

>D>	@	ABBOTT	10,000 UNITS/VIAL	N18663 001	Nov 10, 1982	Mar	CAHN
>A>	@	CHART MEDCL	4,000 UNITS/VIAL	N18663 002	Aug 21, 1984	Mar	CAHN
>A>	@		10,000 UNITS/VIAL	N18663 001	Nov 10, 1982	Mar	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	AB	SANDOZ	200MG	N74100 001	Jan 31, 1995	Mar	DISC
>A>	@		200MG	N74100 001	Jan 31, 1995	Mar	DISC
>D>	AB		300MG	N74100 002	Jan 31, 1995	Mar	DISC
>A>	@		300MG	N74100 002	Jan 31, 1995	Mar	DISC
>D>	AB		400MG	N74100 003	Jan 31, 1995	Mar	DISC
>A>	@		400MG	N74100 003	Jan 31, 1995	Mar	DISC
>D>	AB		800MG	N74100 004	Jan 31, 1995	Mar	DISC
>A>	@		800MG	N74100 004	Jan 31, 1995	Mar	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

>D>	@	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 250MG BASE	N75685 002	Jun 09, 2004	Mar	CMFD
>D>	@		EQ 500MG BASE	N75685 003	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Mar	CMFD
>D>	@		EQ 750MG BASE	N75685 001	Jun 09, 2004	Mar	CMFD
>A>	AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Mar	CMFD
	@	TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jan	DISC
	@		EQ 500MG BASE	N76136 002	Jun 09, 2004	Jan	DISC
	@		EQ 750MG BASE	N76136 003	Jun 09, 2004	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB		AMNEAL PHARMS	EQ 10MG BASE	N77045 003	Apr 29, 2005	Feb	CAHN
AB			EQ 20MG BASE	N77045 002	Apr 29, 2005	Feb	CAHN
AB			EQ 40MG BASE	N77045 001	Apr 29, 2005	Feb	CAHN
AB		GLENMARK GENERICS	EQ 10MG BASE	N77654 001	Feb 27, 2009	Feb	NEWA
AB			EQ 20MG BASE	N77654 002	Feb 27, 2009	Feb	NEWA
AB			EQ 40MG BASE	N77654 003	Feb 27, 2009	Feb	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>D>	AB	SANDOZ	0.1MG	N70887 001	Aug 31, 1988	Mar	DISC
>A>	@		0.1MG	N70887 001	Aug 31, 1988	Mar	DISC
>D>	AB		0.2MG	N70886 001	Aug 31, 1988	Mar	DISC
>A>	@		0.2MG	N70886 001	Aug 31, 1988	Mar	DISC
>D>	AB		0.3MG	N71294 001	Aug 31, 1988	Mar	DISC
>A>	@		0.3MG	N71294 001	Aug 31, 1988	Mar	DISC

CLORAZEPATE DIPOTASSIUM

>D>		CAPSULE; ORAL					
>D>		CLORAZEPATE DIPOTASSIUM					
>D>	+	SANDOZ	3.75MG	N72219 001	Aug 26, 1988	Mar	DISC
>A>	@		3.75MG	N72219 001	Aug 26, 1988	Mar	DISC

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

>D>	AB	SANDOZ	7.5MG	N72513 001	May 11, 1990	Mar	DISC
>A>		@	7.5MG	N72513 001	May 11, 1990	Mar	DISC
>D>	AB		15MG	N72514 001	May 11, 1990	Mar	DISC
>A>		@	15MG	N72514 001	May 11, 1990	Mar	DISC

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

>A>		@ PAR PHARM	0.5MG/INH	N19722 001	Nov 05, 1996	Mar	CAHN
>D>		@ QOL MEDCL	0.5MG/INH	N19722 001	Nov 05, 1996	Mar	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

		@ BAXTER HLTHCARE	100MG/VIAL	N12142 001		Feb	CAHN
		@	200MG/VIAL	N12142 002		Feb	CAHN
		@	500MG/VIAL	N12142 003		Feb	CAHN
		@	1GM/VIAL	N12142 004	Aug 30, 1982	Feb	CAHN
		@	2GM/VIAL	N12142 005	Aug 30, 1982	Feb	CAHN
		LYOPHILIZED CYTOXAN					
	+	BAXTER HLTHCARE	100MG/VIAL	N12142 006	Dec 05, 1985	Feb	CAHN
	+		200MG/VIAL	N12142 007	Dec 10, 1985	Feb	CAHN
AP	+		500MG/VIAL	N12142 008	Jan 04, 1984	Feb	CAHN
AP	+		1GM/VIAL	N12142 010	Sep 24, 1985	Feb	CAHN
AP	+		2GM/VIAL	N12142 009	Dec 10, 1984	Feb	CAHN

TABLET; ORAL

CYTOXAN

		@ BAXTER HLTHCARE	25MG	N12141 002		Feb	CAHN
		@	50MG	N12141 001		Feb	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

		@ DURAMED PHARMS BARR	0.15MG;0.03MG	N75256 001	Aug 12, 1999	Feb	DISC
--	--	-----------------------	---------------	------------	--------------	-----	------

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

	+	ALCON	0.05%;0.3%	N50818 001	Feb 13, 2009	Feb	NEWA
--	---	-------	------------	------------	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

		TAKEDA PHARMS	30MG	N22287 001	Jan 30, 2009	Jan	NEWA
	+		60MG	N22287 002	Jan 30, 2009	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>D>	AA	BARR	10MG	N40361 002	Jan 31, 2001	Mar	CRLD
>A>	AA	+	10MG	N40361 002	Jan 31, 2001	Mar	CRLD
>D>		DEXTROSTAT					
>D>	AA	+	SHIRE	5MG	N84051 001	Mar	DISC
>A>		@	5MG	N84051 001		Mar	DISC

TABLET; ORAL

>D> DEXTROSTAT

>D>	AA	+	SHIRE	10MG	N84051 002		Mar	DISC
>A>			@	10MG	N84051 002		Mar	DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>D>	AB		SANDOZ	2MG	N70302 001	Dec 20, 1985	Mar	DISC
>A>			@	2MG	N70302 001	Dec 20, 1985	Mar	DISC
>D>	AB			5MG	N70303 001	Dec 20, 1985	Mar	DISC
>A>			@	5MG	N70303 001	Dec 20, 1985	Mar	DISC
>D>	AB			10MG	N70304 001	Dec 20, 1985	Mar	DISC
>A>			@	10MG	N70304 001	Dec 20, 1985	Mar	DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

	AA		COREPHARMA	25MG	N40828 001	Nov 05, 2008	Feb	CTEC
	AA	+	WATSON PHARMS	25MG	N11722 002		Feb	CTEC

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D>	AB		SANDOZ	500MG	N74604 001	Jun 10, 1996	Mar	DISC
>A>			@	500MG	N74604 001	Jun 10, 1996	Mar	DISC
>D>	AB	+	TEVA	500MG	N73673 001	Jul 31, 1992	Mar	CTEC
>A>			+	500MG	N73673 001	Jul 31, 1992	Mar	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AA		BARR	50MG	N80738 001		Mar	CRLD
>A>			+	50MG	N80738 001		Mar	CRLD
>D>	AA		LNK	25MG	N87977 001	Jan 27, 1983	Mar	DISC
>A>			@	25MG	N87977 001	Jan 27, 1983	Mar	DISC
>D>	AA			50MG	N87978 001	Jan 27, 1983	Mar	DISC
>A>			@	50MG	N87978 001	Jan 27, 1983	Mar	DISC
>D>	AA	+	SANDOZ	25MG	N80832 001		Mar	DISC
>A>			@	25MG	N80832 001		Mar	DISC
>D>	AA	+		50MG	N80832 002		Mar	DISC
>A>			@	50MG	N80832 002		Mar	DISC
>D>	AA		VALEANT PHARM INTL	50MG	N80592 001		Mar	DISC
>A>			@	50MG	N80592 001		Mar	DISC
>D>	AA		WATSON LABS	25MG	N80728 001		Mar	DISC
>A>			@	25MG	N80728 001		Mar	DISC
>D>	AA			50MG	N80727 001		Mar	DISC
>A>			@	50MG	N80727 001		Mar	DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

>D>	AB		SANDOZ	25MG	N86944 002	Apr 16, 1991	Mar	DISC
>A>			@	25MG	N86944 002	Apr 16, 1991	Mar	DISC
>D>	AB			50MG	N87562 001	Feb 25, 1992	Mar	DISC

TABLET; ORAL

DIPYRIDAMOLE

>A>		@ SANDOZ	50MG	N87562	001	Feb 25, 1992	Mar	DISC
>D>	AB		75MG	N87561	001	Feb 25, 1992	Mar	DISC
>A>		@	75MG	N87561	001	Feb 25, 1992	Mar	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB	+	ABBOTT	EQ 125MG VALPROIC ACID	N19680	001	Sep 12, 1989	Jan	CFTG
----	---	--------	------------------------	--------	-----	--------------	-----	------

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	N78979	001	Jan 23, 2009	Jan	NEWA
AB		ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N78919	001	Jan 27, 2009	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>A>	AB	MYLAN	EQ 125MG VALPROIC ACID	N90062	001	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	N90062	002	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	N90062	003	Mar 17, 2009	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N77100	001	Mar 05, 2009	Feb	NEWA
	AB		EQ 250MG VALPROIC ACID	N77100	002	Mar 05, 2009	Feb	NEWA
	AB		EQ 500MG VALPROIC ACID	N77100	003	Mar 05, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

AB		ABBOTT	EQ 250MG VALPROIC ACID	N21168	002	May 31, 2002	Jan	CFTG
AB	+		EQ 500MG VALPROIC ACID	N21168	001	Aug 04, 2000	Jan	CFTG

DIVALPROEX SODIUM

AB		ANCHEN PHARMS	EQ 250MG VALPROIC ACID	N78445	001	Feb 26, 2009	Feb	NEWA
AB		MYLAN	EQ 250MG VALPROIC ACID	N77567	001	Jan 29, 2009	Jan	NEWA
AB			EQ 500MG VALPROIC ACID	N77567	002	Jan 29, 2009	Jan	NEWA
AB		WOCKHARDT	EQ 250MG VALPROIC ACID	N78705	002	Feb 10, 2009	Jan	NEWA
AB		ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	N78239	001	Feb 27, 2009	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>A>	AT	ALCON	EQ 2% BASE	N78981	001	Apr 13, 2009	Mar	NEWA
-----	----	-------	------------	--------	-----	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

	+	PAR PHARM	EQ 150MG BASE	N65055	003	Jul 15, 2005	Jan	CRLD
--	---	-----------	---------------	--------	-----	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE

>A>	AB	MUTUAL PHARM	EQ 50MG BASE	N65471	001	Apr 17, 2009	Mar	NEWA
>A>	AB		EQ 75MG BASE	N65471	002	Apr 17, 2009	Mar	NEWA
>A>	AB		EQ 100MG BASE	N65471	003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

>D>	AB	PAR PHARM	2.5MG	N78292	001	Jun 27, 2008	Mar	CAHN
>D>	AB		5MG	N78292	002	Jun 27, 2008	Mar	CAHN
>D>	AB		10MG	N78292	003	Jun 27, 2008	Mar	CAHN
>A>	AB	SVC PHARMA	2.5MG	N78292	001	Jun 27, 2008	Mar	CAHN
>A>	AB		5MG	N78292	002	Jun 27, 2008	Mar	CAHN
>A>	AB		10MG	N78292	003	Jun 27, 2008	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

>A>		DROSPIRENONE AND ETHINYL ESTRADIOL					
>A>	AB	BARR	3MG;0.02MG	N78515 001	Mar 30, 2009	Mar	NEWA
		YAZ					
>D>	+	BAYER HLTHCARE	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG
>A>	AB	+	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

>D>	AB	SANDOZ	2.5MG	N75048 001	Aug 22, 2000	Mar	DISC
>A>		@	2.5MG	N75048 001	Aug 22, 2000	Mar	DISC
>D>	AB		5MG	N75048 002	Aug 22, 2000	Mar	DISC
>A>		@	5MG	N75048 002	Aug 22, 2000	Mar	DISC
>D>	AB		10MG	N75048 003	Aug 22, 2000	Mar	DISC
>A>		@	10MG	N75048 003	Aug 22, 2000	Mar	DISC
>D>	AB		20MG	N75048 004	Aug 22, 2000	Mar	DISC
>A>		@	20MG	N75048 004	Aug 22, 2000	Mar	DISC

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	+	HOSPIRA	1.25MG/ML	N75458 001	Aug 22, 2000	Feb	CRLD
		VASOTEC					
		@ BIOVAIL LABS INTL	1.25MG/ML	N19309 001	Feb 09, 1988	Feb	DISC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

		@ ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758 001	Jun 15, 1988	Jan	DISC
--	--	--------	--	------------	--------------	-----	------

PEDIAZOLE

		@ ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529 001		Jan	DISC
--	--	-------------	--	------------	--	-----	------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

		@ HOSPIRA	EQ 1GM BASE/VIAL	N50182 003		Feb	DISC
AP	+		EQ 1GM BASE/VIAL	N62638 002	Oct 31, 1986	Feb	CRLD

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

>D>	AB	STAT-TRADE	100MG	N16320 001		Mar	CAHN
>D>		@	200MG	N16320 002		Mar	CAHN
>D>	AB		400MG	N16320 003		Mar	CAHN
>D>		@	500MG	N16320 004		Mar	CAHN
>A>	AB	STI PHARMA LLC	100MG	N16320 001		Mar	CAHN
>A>		@	200MG	N16320 002		Mar	CAHN
>A>	AB		400MG	N16320 003		Mar	CAHN
>A>		@	500MG	N16320 004		Mar	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

>D> ORTHO-NOVUM 10/11-28

>D> AB + ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG N18354 002 Jan 11, 1982 Mar DISC

>A> @ 0.035MG,0.035MG;0.5MG,1MG N18354 002 Jan 11, 1982 Mar DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OVRAL

>A> @ AKRIMAX PHARMS 0.05MG;0.5MG N16672 001 Mar CAHN

>D> @ WYETH PHARMS INC 0.05MG;0.5MG N16672 001 Mar CAHN

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+ GENPHARM 50MG N75635 001 Sep 19, 2001 Feb CRLD

VEPESID

@ BRISTOL MYERS SQUIBB 50MG N19557 001 Dec 30, 1986 Feb DISC

>A> EVEROLIMUS

TABLET; ORAL

AFINITOR

>A> NOVARTIS 5MG N22334 001 Mar 30, 2009 Mar NEWA

>A> + 10MG N22334 002 Mar 30, 2009 Mar NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>D> AB SANDOZ 20MG N75302 001 Apr 16, 2001 Mar DISC

>A> @ 20MG N75302 001 Apr 16, 2001 Mar DISC

>D> AB 40MG N75302 002 Apr 16, 2001 Mar DISC

>A> @ 40MG N75302 002 Apr 16, 2001 Mar DISC

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS 40MG N21856 001 Feb 13, 2009 Feb NEWA

+ 80MG N21856 002 Feb 13, 2009 Feb NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

@ PEDINOL EQ 300MG BASE N17604 002 Feb DISC

NALFON 200

+ PEDINOL EQ 200MG BASE N17604 003 Feb CRLD

TABLET; ORAL

FENOPROFEN CALCIUM

>D> AB SANDOZ EQ 600MG BASE N72396 001 Oct 17, 1988 Mar DISC

>A> @ EQ 600MG BASE N72396 001 Oct 17, 1988 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>D> AB SANDOZ 50MG N76030 001 Oct 28, 2002 Mar DISC

>A> @ 50MG N76030 001 Oct 28, 2002 Mar DISC

TABLET; ORALFLECAINIDE ACETATE

>D>	AB	SANDOZ	100MG	N76030 002	Oct 28, 2002	Mar	DISC
>A>		@	100MG	N76030 002	Oct 28, 2002	Mar	DISC
>D>	AB		150MG	N76030 003	Oct 28, 2002	Mar	DISC
>A>		@	150MG	N76030 003	Oct 28, 2002	Mar	DISC

FLUDARABINE PHOSPHATEINJECTABLE; INJECTIONFLUDARABINE PHOSPHATE

AP		ACTAVIS TOTOWA	50MG/VIAL	N78610 001	Feb 11, 2009	Feb	NEWA
----	--	----------------	-----------	------------	--------------	-----	------

FLUMAZENILINJECTABLE; INJECTIONFLUMAZENIL

>A>	AP	HIKMA FARMACEUTICA	0.5MG/5ML (0.1MG/ML)	N78527 001	Mar 23, 2009	Mar	NEWA
>A>	AP		1MG/10ML (0.1MG/ML)	N78527 002	Mar 23, 2009	Mar	NEWA

FLUOCINOLONE ACETONIDEOIL; TOPICALDERMA-SMOOTH/FS

		+ HILL DERMAC	0.01%	N19452 002	Nov 09, 2005	Feb	NEWA
--	--	---------------	-------	------------	--------------	-----	------

FLUOROURACILSOLUTION; TOPICALFLUOROPLEX

		@ ELORAC	1%	N16765 001		Feb	CAHN
--	--	----------	----	------------	--	-----	------

FLUOXETINE HYDROCHLORIDECAPSULE; ORALFLUOXETINE HYDROCHLORIDE

>A>	AB1	ALEMBIC LTD	EQ 10MG BASE	N90223 001	Mar 19, 2009	Mar	NEWA
>A>	AB1		EQ 20MG BASE	N90223 002	Mar 19, 2009	Mar	NEWA
>A>	AB		EQ 40MG BASE	N90223 003	Mar 19, 2009	Mar	NEWA
>A>	AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165 001	Feb 01, 2002	Mar	CAHN
>A>	AB1		EQ 20MG BASE	N76165 002	Feb 01, 2002	Mar	CAHN
>D>	AB1	RANBAXY	EQ 10MG BASE	N76165 001	Feb 01, 2002	Mar	CAHN
>D>	AB1		EQ 20MG BASE	N76165 002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORALFLUOXETINE HYDROCHLORIDE

>A>	AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209 001	Mar 20, 2009	Mar	NEWA
-----	----	-----------------	------------------	------------	--------------	-----	------

FLURAZEPAM HYDROCHLORIDECAPSULE; ORALFLURAZEPAM HYDROCHLORIDE

>D>	AB	SANDOZ	15MG	N71716 001	Jul 31, 1991	Mar	DISC
>A>		@	15MG	N71716 001	Jul 31, 1991	Mar	DISC
>D>	AB		30MG	N71717 001	Jul 31, 1991	Mar	DISC
>A>		@	30MG	N71717 001	Jul 31, 1991	Mar	DISC

FLURBIPROFENTABLET; ORALFLURBIPROFEN

>D>	AB	SANDOZ	50MG	N74448 001	Jul 28, 1995	Mar	DISC
>A>		@	50MG	N74448 001	Jul 28, 1995	Mar	DISC
>D>	AB		100MG	N74448 002	Jul 28, 1995	Mar	DISC

TABLET; ORAL

FLURBIPROFEN

>A>	@ SANDOZ	100MG	N74448 002	Jul 28, 1995	Mar	DISC
-----	----------	-------	------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>D>	AB	IVAX PHARMS	25MG	N75898 001	Mar 12, 2001	Mar	DISC
>A>	@		25MG	N75898 001	Mar 12, 2001	Mar	DISC
>D>	AB		50MG	N75898 002	Mar 12, 2001	Mar	DISC
>A>	@		50MG	N75898 002	Mar 12, 2001	Mar	DISC
>D>	AB		100MG	N75898 003	Mar 12, 2001	Mar	DISC
>A>	@		100MG	N75898 003	Mar 12, 2001	Mar	DISC

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

>A>	AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033 001	Apr 07, 2009	Mar	NEWA
-----	----	-------------	----------------------	------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

>D>	AB	SANDOZ	10MG	N76188 001	Oct 08, 2004	Mar	DISC
>A>	@		10MG	N76188 001	Oct 08, 2004	Mar	DISC
>D>	AB		20MG	N76188 002	Oct 08, 2004	Mar	DISC
>A>	@		20MG	N76188 002	Oct 08, 2004	Mar	DISC
>D>	AB		40MG	N76188 003	Oct 08, 2004	Mar	DISC
>A>	@		40MG	N76188 003	Oct 08, 2004	Mar	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MONOPRIL-HCT

	@	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	Nov 30, 1994	Feb	DISC
	@		20MG;12.5MG	N20286 001	Nov 30, 1994	Feb	DISC

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA		ROXANE	4MG/ML	N78185 001	Jan 30, 2009	Jan	NEWA
AA	+	ORTHO MCNEIL JANSSEN	4MG/ML	N21224 001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		PAR PHARM	EQ 4MG BASE	N77604 001	Feb 06, 2009	Jan	NEWA
AB			EQ 8MG BASE	N77604 002	Feb 06, 2009	Jan	NEWA
AB			EQ 12MG BASE	N77604 003	Feb 06, 2009	Jan	NEWA
AB		ROXANE	EQ 4MG BASE	N77608 001	Feb 11, 2009	Jan	NEWA
AB			EQ 8MG BASE	N77608 002	Feb 11, 2009	Jan	NEWA
AB			EQ 12MG BASE	N77608 003	Feb 11, 2009	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>D>	AB	TEVA	5MG	N74388 003	Aug 29, 1995	Mar	CRLD
>A>	AB	+	5MG	N74388 003	Aug 29, 1995	Mar	CRLD

TABLET; ORAL

>D>		MICRONASE						
>D>	AB	PHARMACIA AND UPJOHN	1.25MG	N17498	001	May 01, 1984	Mar	DISC
>A>		@	1.25MG	N17498	001	May 01, 1984	Mar	DISC
>D>	AB		2.5MG	N17498	002	May 01, 1984	Mar	DISC
>A>		@	2.5MG	N17498	002	May 01, 1984	Mar	DISC
>D>	AB	+	5MG	N17498	003	May 01, 1984	Mar	DISC
>A>		@	5MG	N17498	003	May 01, 1984	Mar	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		WEST WARD	1MG	N40836	001	Mar 05, 2009	Feb	NEWA
AA			2MG	N40836	002	Mar 05, 2009	Feb	NEWA

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB		DR REDDYS LABS LTD	EQ 1MG BASE	N78846	001	Feb 27, 2009	Feb	NEWA
----	--	--------------------	-------------	--------	-----	--------------	-----	------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

VANTAS

>A>	+	ENDO PHARMS	50MG	N21732	001	Oct 12, 2004	Mar	CAHN
>D>	+	INDEVUS	50MG	N21732	001	Oct 12, 2004	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

@ ENDO PHARMS 1.5MG/5ML; 5MG/5ML

N05213 002 Jul 26, 1988 Feb DISC

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	+	HI TECH PHARMA	1.5MG/5ML; 5MG/5ML	N40613	001	Feb 08, 2008	Feb	CRLD
----	---	----------------	--------------------	--------	-----	--------------	-----	------

TABLET; ORAL

HYCODAN

@ ENDO PHARMS 1.5MG; 5MG

N05213 001 Jul 26, 1988 Feb DISC

TUSSIGON

AA	+	KING PHARMS	1.5MG; 5MG	N88508	001	Jul 30, 1985	Feb	CRLD
----	---	-------------	------------	--------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

>A>	AP	AKORN	20MG/ML	N40730	001	Apr 21, 2009	Mar	NEWA
-----	----	-------	---------	--------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	SANDOZ	10MG	N83241	001		Mar	DISC
>A>		@	10MG	N83241	001		Mar	DISC
>D>	AA		25MG	N83560	001		Mar	DISC
>A>		@	25MG	N83560	001		Mar	DISC
>D>	AA		50MG	N83561	001		Mar	DISC
>A>		@	50MG	N83561	001		Mar	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	IPCA LABS LTD	12.5MG	N79237	001	Apr 02, 2009	Mar	NEWA
-----	----	---------------	--------	--------	-----	--------------	-----	------

>D> SOLUTION; ORAL
 >D> HYDROCHLOROTHIAZIDE
 >D> + ROXANE 50MG/5ML N88587 001 Jul 02, 1984 Mar DISC
 >A> @ 50MG/5ML N88587 001 Jul 02, 1984 Mar DISC

TABLET; ORAL

HYDROCHLOROTHIAZIDE
 >D> AB SANDOZ 25MG N87565 001 Mar 09, 1982 Mar DISC
 >A> @ 25MG N87565 001 Mar 09, 1982 Mar DISC
 >D> AB 50MG N84912 001 Mar DISC
 >A> @ 50MG N84912 001 Mar DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 >D> AB SANDOZ 25MG;40MG N71060 001 Aug 26, 1987 Mar DISC
 >A> @ 25MG;40MG N71060 001 Aug 26, 1987 Mar DISC
 >D> AB 25MG;80MG N71061 001 Aug 26, 1987 Mar DISC
 >A> @ 25MG;80MG N71061 001 Aug 26, 1987 Mar DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 AB RANBAXY 12.5MG;EQ 10MG BASE N78211 001 Mar 04, 2009 Feb NEWA
 AB 12.5MG;EQ 20MG BASE N78211 002 Mar 04, 2009 Feb NEWA
 AB 25MG;EQ 20MG BASE N78211 003 Mar 04, 2009 Feb NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
 >D> AB SANDOZ 25MG;25MG N86881 001 Mar DISC
 >A> @ 25MG;25MG N86881 001 Mar DISC

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

@ PFIZER 1.5%;EQ 5MG BASE/ML N61016 001 Feb DISC

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB BARR 500MG N75143 001 Oct 16, 1998 Feb CMFD

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D> AB SANDOZ 10MG N87869 001 Dec 20, 1982 Mar DISC
 >A> @ 10MG N87869 001 Dec 20, 1982 Mar DISC
 >D> AB 25MG N87870 001 Dec 20, 1982 Mar DISC
 >A> @ 25MG N87870 001 Dec 20, 1982 Mar DISC
 >D> AB 50MG N87871 001 Dec 20, 1982 Mar DISC
 >A> @ 50MG N87871 001 Dec 20, 1982 Mar DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>D> AB SANDOZ EQ 25MG HCL N81127 001 Jun 28, 1991 Mar DISC

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>A>	@ SANDOZ	EQ 25MG HCL	N81127 001	Jun 28, 1991	Mar	DISC
-----	----------	-------------	------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	+	DR REDDYS LA	800MG	N75682 003	Nov 14, 2001	Feb	CRLD
>D>	AB	SANDOZ	300MG	N70734 001	Jun 12, 1986	Mar	DISC
>A>	@		300MG	N70734 001	Jun 12, 1986	Mar	DISC
>D>	AB		400MG	N70735 001	Jun 12, 1986	Mar	DISC
>A>	@		400MG	N70735 001	Jun 12, 1986	Mar	DISC
>D>	AB		600MG	N70736 001	Jun 12, 1986	Mar	DISC
>A>	@		600MG	N70736 001	Jun 12, 1986	Mar	DISC
>D>	AB		800MG	N72169 001	Dec 11, 1987	Mar	DISC
>A>	@		800MG	N72169 001	Dec 11, 1987	Mar	DISC
AB		SHASUN USA	400MG	N78329 001	Feb 05, 2009	Jan	NEWA
AB			600MG	N78329 002	Feb 05, 2009	Jan	NEWA
AB			800MG	N78329 003	Feb 05, 2009	Jan	NEWA
		MOTRIN					
	@	MCNEIL CONSUMER	400MG	N17463 002		Feb	DISC
	@		600MG	N17463 004		Feb	DISC
	@		800MG	N17463 005	May 22, 1985	Feb	DISC

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

@	BAXTER HLTHCARE	1GM/VIAL	N19763 001	Dec 30, 1988	Feb	CAHN
@		3GM/VIAL	N19763 002	Dec 30, 1988	Feb	CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

+	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763 003	Oct 10, 1992	Feb	CAHN
+		3GM/VIAL;100MG/ML	N19763 004	Oct 10, 1992	Feb	CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

AB	+	SANDOZ	75MG	N74464 001	May 28, 1998	Feb	CTEC
----	---	--------	------	------------	--------------	-----	------

INDOMETHACIN

AB		AVANTHI INC	75MG	N79175 001	Mar 06, 2009	Feb	NEWA
----	--	-------------	------	------------	--------------	-----	------

SUSPENSION; ORAL

INDOCIN

>A>	+	IROKO PHARMS	25MG/5ML	N18332 001	Oct 10, 1985	Mar	CAHN
>D>	+	MERCK	25MG/5ML	N18332 001	Oct 10, 1985	Mar	CAHN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

		SANOFI AVENTIS US	300 UNITS/3ML	N21629 003	Feb 24, 2009	Feb	NEWA
--	--	-------------------	---------------	------------	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP	PHARMAFORCE	40MG/2ML (20MG/ML)	N90016 001	Jan 28, 2009	Mar	NEWA
-----	----	-------------	--------------------	------------	--------------	-----	------

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	PHARMAFORCE	40MG/2ML (20MG/ML)	N90016 001	Jan 28, 2009	Jan	NEWA
>A>	AP	100MG/5ML (20MG/ML)	N90016 002	Jan 28, 2009	Mar	NEWA
AP		100MG/5ML (20MG/ML)	N90016 002	Jan 28, 2009	Jan	NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

>D>	AB	SANDOZ	2.5MG	N86225 001	Feb 19, 1988	Mar	DISC
>A>		@	2.5MG	N86225 001	Feb 19, 1988	Mar	DISC
>D>	AB		5MG	N86222 001	Feb 19, 1988	Mar	DISC
>A>		@	5MG	N86222 001	Feb 19, 1988	Mar	DISC

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

+ STIEFEL LABS INC

2%

N21946 001 Jul 28, 2006 Jan CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

>D>	AB	SANDOZ	50MG	N74024 001	Dec 29, 1995	Mar	DISC
>A>		@	50MG	N74024 001	Dec 29, 1995	Mar	DISC
>D>	AB		75MG	N74024 002	Dec 29, 1995	Mar	DISC
>A>		@	75MG	N74024 002	Dec 29, 1995	Mar	DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	APOTEX INC	25MG	N78625 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625 004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956 004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132 004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N76708 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708 004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428 004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443 001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443 002	Feb 11, 2009	Jan	NEWA
AB		150MG	N78443 003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443 004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420 002	Jan 27, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	MYLAN	150MG	N77420 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420 004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392 004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645 004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525 004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947 004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310 001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310 002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310 003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310 004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982 004	Jan 27, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA	25MG	N77633 001	Jan 27, 2009	Jan	NEWA
		50MG	N77633 002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633 003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633 004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633 005	Jan 27, 2009	Jan	NEWA
AB		250MG	N77633 006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099 001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099 002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204 001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204 002	Feb 04, 2009	Jan	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	SUN PHARMA GLOBAL	1MG/0.2ML	N78885 001	Mar 09, 2009	Feb	NEWA
----	-------------------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>							
>A>	AN	DEY	EQ 0.25% BASE	N78309 001	Mar 20, 2009	Mar	NEWA
		XOPENEX					
>D>	+	SEPRACOR	EQ 0.25% BASE	N20837 004	Jul 18, 2003	Mar	CFTG
>A>	AN	+	EQ 0.25% BASE	N20837 004	Jul 18, 2003	Mar	CFTG

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

>A>	AA	SILARX	100MG/ML	N90263 001	Apr 03, 2009	Mar	NEWA
	AA	TARO	100MG/ML	N78774 001	Feb 10, 2009	Jan	NEWA

TABLET; ORAL

LEVETIRACETAM

>A>	AB	APOTEX INC	250MG	N78869 001	Mar 13, 2009	Mar	NEWA
>A>	AB		500MG	N78869 002	Mar 13, 2009	Mar	NEWA
>A>	AB		750MG	N78869 003	Mar 13, 2009	Mar	NEWA
>A>	AB		1GM	N78869 004	Mar 13, 2009	Mar	NEWA
>A>	AB	CIPLA LTD	250MG	N77319 001	Mar 20, 2009	Mar	NEWA
>A>	AB		500MG	N77319 002	Mar 20, 2009	Mar	NEWA
>A>	AB		750MG	N77319 003	Mar 20, 2009	Mar	NEWA
	AB	GENPHARM ULC	250MG	N78731 001	Feb 10, 2009	Jan	NEWA
	AB		500MG	N78731 002	Feb 10, 2009	Jan	NEWA
	AB		750MG	N78731 003	Feb 10, 2009	Jan	NEWA
	AB		1GM	N78731 004	Feb 10, 2009	Jan	NEWA
	AB	SOLCO HLTHCARE	250MG	N78106 001	Feb 10, 2009	Jan	NEWA
	AB		500MG	N78106 002	Feb 10, 2009	Jan	NEWA
	AB		750MG	N78106 003	Feb 10, 2009	Jan	NEWA
	AB		1GM	N78106 004	Feb 10, 2009	Jan	NEWA
	AB	WATSON LABS FLORIDA	250MG	N77408 001	Mar 02, 2009	Feb	NEWA
	AB		500MG	N77408 002	Mar 02, 2009	Feb	NEWA
	AB		750MG	N77408 003	Mar 02, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

UCB INC

			500MG	N22285 001	Sep 12, 2008	Feb	CRLD
--	--	--	-------	------------	--------------	-----	------

	+		750MG	N22285 002	Feb 12, 2009	Feb	NEWA
--	---	--	-------	------------	--------------	-----	------

LINDANE

SHAMPOO; TOPICAL

LINDANE

AT	+	OLTA PHARMS	1%	N87266 001		Jan	CAHN
----	---	-------------	----	------------	--	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

>D>		KING PHARMS	EQ 0.005MG BASE	N10379 001		Mar	CFTG
>A>	AB		EQ 0.005MG BASE	N10379 001		Mar	CFTG
>D>			EQ 0.025MG BASE	N10379 002		Mar	CTEC
>A>	AB		EQ 0.025MG BASE	N10379 002		Mar	CTEC
>D>	+		EQ 0.05MG BASE	N10379 003		Mar	CTEC
>A>	AB	+	EQ 0.05MG BASE	N10379 003		Mar	CTEC
>A>		LIOTHYRONINE SODIUM					
>A>	AB	COASTAL PHARMS	EQ 0.005MG BASE	N90097 001	Mar 20, 2009	Mar	NEWA
>A>	AB		EQ 0.025MG BASE	N90097 002	Mar 20, 2009	Mar	NEWA
>A>	AB		EQ 0.05MG BASE	N90097 003	Mar 20, 2009	Mar	NEWA

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB		GLENMARK GENERICS	150MG	N79139 001	Feb 03, 2009	Jan	NEWA
AB			300MG	N79139 002	Feb 03, 2009	Jan	NEWA
AB			600MG	N79139 003	Feb 03, 2009	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

>D>	AB	SANDOZ	2MG	N72993 001	Aug 28, 1992	Mar	DISC
>A>		@	2MG	N72993 001	Aug 28, 1992	Mar	DISC

LORAZEPAM

>D> SOLUTION; ORAL

>D> LORAZEPAM

>D>		ROXANE	0.5MG/5ML	N74648 001	Mar 18, 1997	Mar	DISC
>A>		@	0.5MG/5ML	N74648 001	Mar 18, 1997	Mar	DISC

MALATHION

LOTION; TOPICAL

MALATHION

AT		SYNERX PHARMA	0.5%	N78743 001	Mar 06, 2009	Feb	NEWA
AT	+	TARO PHARMS NORTH	0.5%	N18613 001	Aug 02, 1982	Feb	CFTG

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	PFIZER	12.5MG	N10721 006		Jan	CAHN
AA	+		25MG	N10721 004		Jan	CAHN
AA	+		50MG	N10721 001	Jan 20, 1982	Jan	CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

>D>	AB	SANDOZ	EQ 50MG BASE	N72262 001	Nov 29, 1988	Mar	DISC
>A>		@	EQ 50MG BASE	N72262 001	Nov 29, 1988	Mar	DISC
>D>	AB		EQ 100MG BASE	N72263 001	Nov 29, 1988	Mar	DISC
>A>		@	EQ 100MG BASE	N72263 001	Nov 29, 1988	Mar	DISC

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA		ALEMBIC LTD	200MG	N90122 001	Feb 18, 2009	Feb	NEWA
AA			400MG	N90122 002	Feb 18, 2009	Feb	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+		STIEFEL LABS INC	2%;0.01%	N20922 001	Dec 10, 1999	Jan	CAHN
---	--	------------------	----------	------------	--------------	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@		BOEHRINGER INGELHEIM	0.4%	N18761 002	Oct 10, 1986	Feb	DISC
@			0.6%	N18761 001	Jun 30, 1983	Feb	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		ALVOGEN	500MG	N76033 001	Jan 24, 2002	Jan	CAHN
----	--	---------	-------	------------	--------------	-----	------

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	ALVOGEN	850MG	N76033 002	Jan 24, 2002	Jan	CAHN
AB		1GM	N76033 003	Jan 24, 2002	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	SANDOZ	500MG	N76223 001	Dec 14, 2004	Mar	DISC
>A>	@		500MG	N76223 001	Dec 14, 2004	Mar	DISC

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@ SOLCO HLTHCARE

500MG

N86989 001

Jan CAHN

@

750MG

N86988 001

Jan CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>A>	AP	EBEWE PARENTA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	N90039 001	Mar 31, 2009	Mar	NEWA
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039 002	Mar 31, 2009	Mar	NEWA
>A>	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029 001	Mar 31, 2009	Mar	NEWA

METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

>D>	AB	ABBOTT	2.5MG	N12524 001		Mar	CTEC
>A>			2.5MG	N12524 001		Mar	CTEC

METHYLCLOTHIAZIDE

>D>	AB	SANDOZ	2.5MG	N89835 001	Aug 18, 1988	Mar	DISC
>A>	@		2.5MG	N89835 001	Aug 18, 1988	Mar	DISC
>D>	AB		5MG	N89837 001	Aug 18, 1988	Mar	DISC
>A>	@		5MG	N89837 001	Aug 18, 1988	Mar	DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>D>	AB	SANDOZ	125MG	N71700 001	Mar 02, 1988	Mar	DISC
>A>	@		125MG	N71700 001	Mar 02, 1988	Mar	DISC
>D>	AB		250MG	N18934 001	Jun 29, 1984	Mar	DISC
>A>	@		250MG	N18934 001	Jun 29, 1984	Mar	DISC
>D>	AB		500MG	N18934 002	Jun 29, 1984	Mar	DISC
>A>	@		500MG	N18934 002	Jun 29, 1984	Mar	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ	40MG/ML	N40719 001	Jan 29, 2009	Jan	NEWA
AB		40MG/ML	N40794 001	Mar 05, 2009	Feb	NEWA
AB		80MG/ML	N40719 002	Jan 29, 2009	Jan	NEWA
AB		80MG/ML	N40794 002	Mar 05, 2009	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE

>D>		@ VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	Jan 26, 2001	Mar	CMFD
-----	--	--------------	-----------------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	Jan 26, 2001	Mar	CMFD
-----	----	------------	-----------------	------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 5MG BASE	N74478 001	Oct 05, 1995	Mar	DISC
-----	----	--------	-------------	------------	--------------	-----	------

>A>		@	EQ 5MG BASE	N74478 001	Oct 05, 1995	Mar	DISC
-----	--	---	-------------	------------	--------------	-----	------

>D>	AB		EQ 10MG BASE	N72215 001	Jan 30, 1990	Mar	DISC
-----	----	--	--------------	------------	--------------	-----	------

>A>		@	EQ 10MG BASE	N72215 001	Jan 30, 1990	Mar	DISC
-----	--	---	--------------	------------	--------------	-----	------

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

		@ SOLCO HLTHCARE	50MG	N74453 001	Apr 27, 1995	Jan	CAHN
--	--	------------------	------	------------	--------------	-----	------

		@	100MG	N74453 002	Apr 27, 1995	Jan	CAHN
--	--	---	-------	------------	--------------	-----	------

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

>A>	AB	ALEMBIC LTD	250MG	N79067 001	Mar 13, 2009	Mar	NEWA
-----	----	-------------	-------	------------	--------------	-----	------

>A>	AB		500MG	N79067 002	Mar 13, 2009	Mar	NEWA
-----	----	--	-------	------------	--------------	-----	------

>D>	AB	SANDOZ	250MG	N18740 001	Oct 22, 1982	Mar	DISC
-----	----	--------	-------	------------	--------------	-----	------

>A>		@	250MG	N18740 001	Oct 22, 1982	Mar	DISC
-----	--	---	-------	------------	--------------	-----	------

>D>	AB		500MG	N18740 002	Oct 22, 1982	Mar	DISC
-----	----	--	-------	------------	--------------	-----	------

>A>		@	500MG	N18740 002	Oct 22, 1982	Mar	DISC
-----	--	---	-------	------------	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>D>	AB	SANDOZ	150MG	N74450 001	May 16, 1996	Mar	DISC
-----	----	--------	-------	------------	--------------	-----	------

>A>		@	150MG	N74450 001	May 16, 1996	Mar	DISC
-----	--	---	-------	------------	--------------	-----	------

>D>	AB		200MG	N74450 002	May 16, 1996	Mar	DISC
-----	----	--	-------	------------	--------------	-----	------

>A>		@	200MG	N74450 002	May 16, 1996	Mar	DISC
-----	--	---	-------	------------	--------------	-----	------

>D>	AB		250MG	N74450 003	May 16, 1996	Mar	DISC
-----	----	--	-------	------------	--------------	-----	------

>A>		@	250MG	N74450 003	May 16, 1996	Mar	DISC
-----	--	---	-------	------------	--------------	-----	------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+		STIEFEL LABS INC	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Jan	CAHN
---	--	------------------	------------------	------------	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

		CYPRESS BIOSCIENCE	12.5MG	N22256 001	Jan 14, 2009	Jan	NEWA
--	--	--------------------	--------	------------	--------------	-----	------

			25MG	N22256 002	Jan 14, 2009	Jan	NEWA
--	--	--	------	------------	--------------	-----	------

			50MG	N22256 003	Jan 14, 2009	Jan	NEWA
--	--	--	------	------------	--------------	-----	------

+			100MG	N22256 004	Jan 14, 2009	Jan	NEWA
---	--	--	-------	------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	BARR	EQ 45MG BASE	N65485 001	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 90MG BASE	N65485 002	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 135MG BASE	N65485 003	Mar 17, 2009	Mar	NEWA
	AB	IMPAX LABS INC	EQ 45MG BASE	N90024 001	Feb 03, 2009	Jan	NEWA
	AB		EQ 90MG BASE	N90024 002	Feb 03, 2009	Jan	NEWA
	AB		EQ 135MG BASE	N90024 003	Feb 03, 2009	Jan	NEWA
		SOLODYN					
	AB	MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	Jan	CFTG
	AB		EQ 90MG BASE	N50808 002	May 08, 2006	Jan	CFTG
	AB	+	EQ 135MG BASE	N50808 003	May 08, 2006	Jan	CFTG

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>A>	AP	GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980 001	Apr 13, 2009	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980 002	Apr 13, 2009	Mar	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

	+	ACTAVIS ELIZABETH	10MG	N20616 008	Apr 20, 2007	Feb	CRLD
	+		80MG	N20616 006	Oct 27, 2006	Feb	CRLD

NABUMETONE

TABLET; ORAL

NABUMETONE

	AB	ACTAVIS ELIZABETH	500MG	N79093 001	Feb 27, 2009	Feb	NEWA
	AB		750MG	N79093 002	Feb 27, 2009	Feb	NEWA
>D>	AB	SANDOZ	500MG	N75590 001	Feb 25, 2002	Mar	DISC
>A>		@	500MG	N75590 001	Feb 25, 2002	Mar	DISC
>D>	AB		750MG	N75590 002	Feb 25, 2002	Mar	DISC
>A>		@	750MG	N75590 002	Feb 25, 2002	Mar	DISC

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

>D>	AB	+	STAT TRADE	EQ 375MG BASE	N20353 001	Jan 05, 1996	Mar	CTEC
>A>		+		EQ 375MG BASE	N20353 001	Jan 05, 1996	Mar	CTEC
>D>	AB	+		EQ 500MG BASE	N20353 002	Jan 05, 1996	Mar	CTEC
>A>		+		EQ 500MG BASE	N20353 002	Jan 05, 1996	Mar	CTEC
>D>			NAPROXEN SODIUM					
>D>	AB		WATSON LABS FLORIDA	EQ 375MG BASE	N75416 002	Apr 23, 2003	Mar	DISC
>A>		@		EQ 375MG BASE	N75416 002	Apr 23, 2003	Mar	DISC
>D>	AB			EQ 500MG BASE	N75416 001	Aug 27, 2002	Mar	DISC
>A>		@		EQ 500MG BASE	N75416 001	Aug 27, 2002	Mar	DISC

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

>D>	AB	BARR	30MG	N77811 001	May 02, 2007	Mar	CRLD
-----	----	------	------	------------	--------------	-----	------

CAPSULE; ORAL

NIMODIPINE

>A>	AB	+	BARR	30MG	N77811	001	May 02, 2007	Mar	CRLD
			NIMOTOP						
			@ BAYER PHARMS	30MG	N18869	001	Dec 28, 1988	Feb	DISC

NITISINONE

CAPSULE; ORAL

ORFADIN

>A>			RARE DIS	2MG	N21232	001	Jan 18, 2002	Mar	CAHN
>A>				5MG	N21232	002	Jan 18, 2002	Mar	CAHN
>A>		+		10MG	N21232	003	Jan 18, 2002	Mar	CAHN
>D>			SWEDISH ORPHAN	2MG	N21232	001	Jan 18, 2002	Mar	CAHN
>D>				5MG	N21232	002	Jan 18, 2002	Mar	CAHN
>D>		+		10MG	N21232	003	Jan 18, 2002	Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

>D>	AB		SANDOZ	25MG	N74336	001	Jan 25, 1995	Mar	DISC
>A>			@	25MG	N74336	001	Jan 25, 1995	Mar	DISC
>D>	AB			50MG	N74336	002	Jan 25, 1995	Mar	DISC
>A>			@	50MG	N74336	002	Jan 25, 1995	Mar	DISC
>D>	AB			100MG	N74336	003	Jan 25, 1995	Mar	DISC
>A>			@	100MG	N74336	003	Jan 25, 1995	Mar	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT			FDC LTD	0.3%	N78559	001	Feb 25, 2009	Feb	NEWA
----	--	--	---------	------	--------	-----	--------------	-----	------

TABLET; ORAL

FLOXIN

>D>									
>D>	AB		ORTHO MCNEIL JANSSEN	200MG	N19735	001	Dec 28, 1990	Mar	DISC
>A>			@	200MG	N19735	001	Dec 28, 1990	Mar	DISC
>D>	AB			300MG	N19735	002	Dec 28, 1990	Mar	DISC
>A>			@	300MG	N19735	002	Dec 28, 1990	Mar	DISC
>D>	AB			400MG	N19735	003	Dec 28, 1990	Mar	DISC
>A>			@	400MG	N19735	003	Dec 28, 1990	Mar	DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

>A>	AB		DR REDDYS LABS	40MG	N78490	001	Apr 17, 2009	Mar	NEWA
>A>	AB		DR REDDYS LABS LTD	10MG	N78693	001	Mar 16, 2009	Mar	NEWA
>A>	AB			20MG	N78693	002	Mar 16, 2009	Mar	NEWA
	AB		KREMERS URBAN DEV	40MG	N75410	003	Jan 23, 2009	Jan	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

>A>	AP		BEDFORD LABS	EQ 0.64MG BASE/ML	N78291	001	Apr 13, 2009	Mar	NEWA
-----	----	--	--------------	-------------------	--------	-----	--------------	-----	------

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>D>	AB		SANDOZ	600MG	N75850	001	Apr 27, 2001	Mar	DISC
-----	----	--	--------	-------	--------	-----	--------------	-----	------

TABLET; ORAL

OXAPROZIN

>A>	@ SANDOZ	600MG	N75850 001	Apr 27, 2001	Mar	DISC
-----	----------	-------	------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

>A>						
>A>	+ WATSON LABS	10%(100MG/PACKET)	N22204 001	Jan 27, 2009	Mar	CTNA
>D>						
>D>	+ WATSON LABS	10%(100MG/PACKET)	N22204 001	Jan 27, 2009	Mar	CTNA
>D>	+	10%(100MG/PACKET)	N22204 001	Jan 27, 2009	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYIN CHLORIDE

AB	OSMOTICA PHARM	5MG	N78503 001	Feb 04, 2009	Jan	NEWA
AB		10MG	N78503 002	Feb 04, 2009	Jan	NEWA
AB		15MG	N78503 003	Feb 04, 2009	Jan	NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	SUN PHARM INDS INC	5MG	N90659 001	Apr 10, 2009	Mar	NEWA
>A>	AB		15MG	N90659 002	Apr 10, 2009	Mar	NEWA
>A>	AB		30MG	N90659 003	Apr 10, 2009	Mar	NEWA
>A>	AB	VINTAGE PHARMS	5MG	N77712 003	Mar 02, 2009	Mar	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	GENERAMEDIX	30MG/VIAL	N78300 001	Mar 10, 2009	Feb	NEWA
AP		90MG/VIAL	N78300 002	Mar 10, 2009	Feb	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

>A>	AB	KUDCO IRELAND	EQ 20MG BASE	N78281 001	Mar 17, 2009	Mar	NEWA
>A>	AB		EQ 40MG BASE	N78281 002	Mar 17, 2009	Mar	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

VEETIDS

>D>							
>D>	AA	APOTHECON	EQ 125MG BASE/5ML	N61410 001		Mar	DISC
>A>	@		EQ 125MG BASE/5ML	N61410 001		Mar	DISC
>D>	AA		EQ 250MG BASE/5ML	N61410 002		Mar	DISC
>A>	@		EQ 250MG BASE/5ML	N61410 002		Mar	DISC

PHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

@	IVAX PHARMS	100MG PROMPT	N80259 001		Jan	DISC
---	-------------	--------------	------------	--	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

>D>	AB	SANDOZ	5MG	N73608 001	Mar 29, 1993	Mar	DISC
>A>	@		5MG	N73608 001	Mar 29, 1993	Mar	DISC
>D>	AB		10MG	N73609 001	Mar 29, 1993	Mar	DISC

TABLET; ORAL

PINDOLOL

>A>	@ SANDOZ	10MG	N73609 001	Mar 29, 1993	Mar	DISC
-----	----------	------	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA	GAVIS PHARMS	17GM/SCOOPFUL	N77736 001	May 26, 2006	Jan	CAHN
	@ TEVA PHARMS	17GM/SCOOPFUL	N77445 001	May 04, 2006	Jan	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

>D>	AA	+	BRAINTREE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	Mar	CTEC
>A>		+		236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT	N19011 001	Jul 13, 1984	Mar	CTEC

FOR SUSPENSION; ORAL

CO-LAV

>D>	AA		BOCA PHARMA	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	N73428 001	Jan 28, 1992	Mar	DISC
>A>		@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	N73428 001	Jan 28, 1992	Mar	DISC
>D>			GO-EVAC					
>D>	AA		BOCA PHARMA	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT	N73433 001	Apr 28, 1992	Mar	DISC
>A>		@		236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT	N73433 001	Apr 28, 1992	Mar	DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

@ KV PHARM

8MEQ

N18238 001

Feb DISC

MICRO-K 10

@ KV PHARM

10MEQ

N18238 002

May 14, 1984 Feb DISC

POTASSIUM CHLORIDE

@ KV PHARM

10MEQ

N70980 001

Feb 17, 1987 Feb DISC

WATSON LABS FLORIDA

8MEQ

N77419 001

Jun 02, 2008 Feb CTEC

+

10MEQ

N77419 002

Jun 02, 2008 Feb CRLD

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	+	WATSON LABS FLORIDA	10MEQ	N75604 001	Apr 10, 2002	Jan	CRLD
----	---	---------------------	-------	------------	--------------	-----	------

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

>D>	AB		SANDOZ	EQ 1MG BASE	N72576 001	May 16, 1989	Mar	DISC
>A>		@		EQ 1MG BASE	N72576 001	May 16, 1989	Mar	DISC
>D>	AB			EQ 2MG BASE	N72577 001	May 16, 1989	Mar	DISC
>A>		@		EQ 2MG BASE	N72577 001	May 16, 1989	Mar	DISC
>D>	AB			EQ 5MG BASE	N72578 001	May 16, 1989	Mar	DISC
>A>		@		EQ 5MG BASE	N72578 001	May 16, 1989	Mar	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	AMNEAL PHARMS	EQ 15MG BASE/5ML	N78345 001	Mar 10, 2009	Feb	NEWA
----	---------------	------------------	------------	--------------	-----	------

PREDNISONE

TABLET; ORAL

PREDNISONE

>D>	AB	SANDOZ	10MG	N89983	001	Jan 12, 1989	Mar	DISC
>A>		@	10MG	N89983	001	Jan 12, 1989	Mar	DISC
>D>	AB		50MG	N89984	001	Jan 12, 1989	Mar	DISC
>A>		@	50MG	N89984	001	Jan 12, 1989	Mar	DISC

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>A>	AA	SUN PHARM INDS INC	6.25MG/5ML	N40891	001	Mar 13, 2009	Mar	NEWA
-----	----	--------------------	------------	--------	-----	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

>D>		@ HERITAGE PHARMS INC	65MG	N80530	001		Mar	CMFD
>A>	AA		65MG	N80530	001		Mar	CMFD

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

	AB	UPSHER SMITH	60MG	N78311	001	Mar 06, 2009	Feb	NEWA
	AB		80MG	N78311	002	Mar 06, 2009	Feb	NEWA
	AB		120MG	N78311	003	Mar 06, 2009	Feb	NEWA
	AB		160MG	N78311	004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	AB	SANDOZ	10MG	N70663	001	Jun 13, 1986	Mar	DISC
>A>		@	10MG	N70663	001	Jun 13, 1986	Mar	DISC
>D>	AB		20MG	N70664	001	Jun 13, 1986	Mar	DISC
>A>		@	20MG	N70664	001	Jun 13, 1986	Mar	DISC
>D>	AB		40MG	N70665	001	Jun 13, 1986	Mar	DISC
>A>		@	40MG	N70665	001	Jun 13, 1986	Mar	DISC
>D>	AB		60MG	N70666	001	Oct 10, 1986	Mar	DISC
>A>		@	60MG	N70666	001	Oct 10, 1986	Mar	DISC
>D>	AB		80MG	N70667	001	Jun 13, 1986	Mar	DISC
>A>		@	80MG	N70667	001	Jun 13, 1986	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

>D>	AA	SANDOZ	60MG;2.5MG	N88602	001	Apr 11, 1985	Mar	DISC
>A>		@	60MG;2.5MG	N88602	001	Apr 11, 1985	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

>D>	AA	+	SANDOZ	60MG;2.5MG	N88193	001	May 17, 1983	Mar	CTEC
>A>		+		60MG;2.5MG	N88193	001	May 17, 1983	Mar	CTEC

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

	AB	RANBAXY	5MG	N78849	001	Mar 06, 2009	Feb	NEWA
	AB		10MG	N78849	002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312 001	Sep 02, 2008	Feb	CTNA
AA	WOCKHARDT	EQ 15MG BASE/ML	N79212 001	Feb 23, 2009	Feb	NEWA

RISPERIDONE

SOLUTION; ORAL

RISPERDAL

AA	+ ORTHO MCNEIL JANSSEN	1MG/ML	N20588 001	Jun 10, 1996	Jan	CFTG
----	------------------------	--------	------------	--------------	-----	------

RISPERIDONE

AA	TEVA	1MG/ML	N76440 001	Jan 30, 2009	Jan	NEWA
----	------	--------	------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

>A>	AB	CADISTA PHARMS	0.25MG	N78828 001	Mar 23, 2009	Mar	NEWA
>A>	AB		0.5MG	N78828 002	Mar 23, 2009	Mar	NEWA
>A>	AB		1MG	N78828 003	Mar 23, 2009	Mar	NEWA
>A>	AB		2MG	N78828 004	Mar 23, 2009	Mar	NEWA
>A>	AB		3MG	N78828 005	Mar 23, 2009	Mar	NEWA
>A>	AB		4MG	N78828 006	Mar 23, 2009	Mar	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	ORTHO MCNEIL JANSSEN	0.5MG	N21444 001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444 003	Apr 02, 2003	Feb	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328 001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328 003	Feb 24, 2009	Feb	NEWA

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	AUSTARPHARMA LLC	EQ 25MG BASE	N78677 001	Mar 04, 2009	Feb	NEWA
AB		EQ 50MG BASE	N78677 002	Mar 04, 2009	Feb	NEWA
AB		EQ 100MG BASE	N78677 003	Mar 04, 2009	Feb	NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>A>	AB	LUPIN	5MG	N78103 005	Apr 14, 2009	Mar	NEWA
-----	----	-------	-----	------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

>A>	AA	KVK TECH	454GM/BOT	N40905 001	Mar 30, 2009	Mar	NEWA
-----	----	----------	-----------	------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN NORDIFLEX

>A>		NOVO NORDISK INC	30MG/3ML	N21148 007	Mar 10, 2009	Mar	NEWA
-----	--	------------------	----------	------------	--------------	-----	------

STANZOLOL

TABLET; ORAL

WINSTROL

>A>		@ LUNDBECK INC	2MG	N12885 001	May 14, 1984	Mar	CAHN
>D>		@ OVATION PHARMS	2MG	N12885 001	May 14, 1984	Mar	CAHN

STAVUDINE

FOR SOLUTION; ORAL

STAVUDINE

>A>	AA	CIPLA LTD	1MG/ML	N78030 001	Mar 20, 2009	Mar	NEWA
-----	----	-----------	--------	------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

>A>	+	LUNDBECK INC	100MG	N19998 002	Jan 30, 1991	Mar	CAHN
>D>	+	OVATION PHARMS	100MG	N19998 002	Jan 30, 1991	Mar	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

>A>	AB	PERRIGO CO TENNESSEE	10%	N78649 001	Mar 23, 2009	Mar	NEWA
-----	----	----------------------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOPRIM

>D>		@ PAR PHARM	400MG;80MG	N70022 001	Feb 15, 1985	Mar	CMFD
>A>	AB		400MG;80MG	N70022 001	Feb 15, 1985	Mar	CMFD

SULFAMETHOPRIM-DS

>D>		@ PAR PHARM	800MG;160MG	N70032 001	Feb 15, 1985	Mar	CMFD
>A>	AB		800MG;160MG	N70032 001	Feb 15, 1985	Mar	CMFD

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AB	SANDOZ	800MG;160MG	N70890 001	Nov 13, 1986	Mar	DISC
>A>		@	800MG;160MG	N70890 001	Nov 13, 1986	Mar	DISC

SULINDAC

TABLET; ORAL

SULINDAC

>D>	AB	SANDOZ	150MG	N72712 001	Aug 30, 1991	Mar	DISC
>A>		@	150MG	N72712 001	Aug 30, 1991	Mar	DISC
>D>	AB		200MG	N72713 001	Aug 30, 1991	Mar	DISC
>A>		@	200MG	N72713 001	Aug 30, 1991	Mar	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N20080 001	Dec 28, 1992	Jan	CFTG
----	---	-----------------	-------------------------------------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP		APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79242 001	Mar 02, 2009	Feb	NEWA
AP		BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79123 001	Feb 06, 2009	Jan	NEWA
AP		SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78067 002	Feb 06, 2009	Jan	NEWA
AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78067 001	Feb 06, 2009	Jan	NEWA
AP		TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78318 001	Feb 06, 2009	Jan	NEWA
AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78318 002	Feb 06, 2009	Jan	NEWA
AP			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77907 001	Feb 06, 2009	Jan	NEWA
AP		WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78593 001	Feb 06, 2009	Jan	NEWA

TABLET; ORAL

IMITREX

AB	GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002	Jun 01, 1995	Jan	CFTG
AB		EQ 50MG BASE	N20132 003	Jun 01, 1995	Jan	CFTG
AB	+	EQ 100MG BASE	N20132 001	Jun 01, 1995	Jan	CFTG

SUMATRIPTAN SUCCINATE

AB	RANBAXY	EQ 100MG BASE	N76572 001	Feb 09, 2009	Jan	NEWA
AB	TEVA	EQ 25MG BASE	N76840 001	Feb 09, 2009	Jan	NEWA
AB		EQ 50MG BASE	N76840 002	Feb 09, 2009	Jan	NEWA
AB		EQ 100MG BASE	N76840 003	Feb 09, 2009	Jan	NEWA

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

>A>	CPPI CV	EQ 37.5MG BASE	N21938 004	Mar 31, 2009	Mar	NEWA
-----	---------	----------------	------------	--------------	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

>D>	AB	ROXANE	EQ 10MG BASE	N76027 001	Feb 20, 2003	Mar	DISC
>A>		@	EQ 10MG BASE	N76027 001	Feb 20, 2003	Mar	DISC
>D>	AB		EQ 20MG BASE	N76027 002	Feb 20, 2003	Mar	DISC
>A>		@	EQ 20MG BASE	N76027 002	Feb 20, 2003	Mar	DISC

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

>A>	@	NOVEL LABS INC	30MG	N71457 001	Apr 21, 1987	Mar	CAHN
>D>	@	PAR PHARM	30MG	N71457 001	Apr 21, 1987	Mar	CAHN

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

	+	SCHERING	100MG/VIAL	N22277 001	Feb 27, 2009	Feb	NEWA
--	---	----------	------------	------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

>D>	AB	ABBOTT	EQ 1MG BASE	N19057 001	Aug 07, 1987	Mar	CTEC
>A>			EQ 1MG BASE	N19057 001	Aug 07, 1987	Mar	CTEC
>D>	AB	+	EQ 2MG BASE	N19057 002	Aug 07, 1987	Mar	CTEC
>A>		+	EQ 2MG BASE	N19057 002	Aug 07, 1987	Mar	CTEC
>D>	AB		EQ 5MG BASE	N19057 003	Aug 07, 1987	Mar	CTEC
>A>			EQ 5MG BASE	N19057 003	Aug 07, 1987	Mar	CTEC
>D>	AB		EQ 10MG BASE	N19057 004	Aug 07, 1987	Mar	CTEC
>A>			EQ 10MG BASE	N19057 004	Aug 07, 1987	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 1MG BASE	N74315 001	Dec 31, 1998	Mar	DISC
>A>		@	EQ 1MG BASE	N74315 001	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 2MG BASE	N74315 002	Dec 31, 1998	Mar	DISC
>A>		@	EQ 2MG BASE	N74315 002	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 5MG BASE	N74315 003	Dec 31, 1998	Mar	DISC
>A>		@	EQ 5MG BASE	N74315 003	Dec 31, 1998	Mar	DISC
>D>	AB		EQ 10MG BASE	N74315 004	Dec 31, 1998	Mar	DISC
>A>		@	EQ 10MG BASE	N74315 004	Dec 31, 1998	Mar	DISC

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

	LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318 002	Jun 25, 2008	Feb	NEWA
+		0.75MG/3ML (0.25MG/ML)	N21318 001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

>D>	AB	+	UNIMED PHARMS	1% (5GM/PACKET)	N21015 002	Feb 28, 2000	Mar	CTEC
>D>	AB			1% (2.5GM/PACKET)	N21015 001	Feb 28, 2000	Mar	CTEC
>A>				1% (2.5GM/PACKET)	N21015 001	Feb 28, 2000	Mar	CTEC
>A>	BX	+		1% (5GM/PACKET)	N21015 002	Feb 28, 2000	Mar	CTEC
>D>			TESTOSTERONE					
>D>	AB		WATSON LABS	1% (2.5GM/PACKET)	N76737 001	Jan 27, 2006	Mar	DISC
>D>	AB			1% (5GM/PACKET)	N76737 002	Jan 27, 2006	Mar	DISC
>A>			@	1% (5GM/PACKET)	N76737 002	Jan 27, 2006	Mar	DISC
>A>			@	1% (2.5GM/PACKET)	N76737 001	Jan 27, 2006	Mar	DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

>A>			@ ENDO PHARMS	200MG/ML	N09165 001		Mar	CAHN
>A>	AO	+		200MG/ML	N09165 003		Mar	CAHN
>D>	AO	+	INDEVUS PHARMS	200MG/ML	N09165 003		Mar	CAHN
>D>			@	200MG/ML	N09165 001		Mar	CAHN

THEOPHYLLINE

>D>			SOLUTION; ORAL					
>D>			THEOPHYLLINE					
>D>		+	ROXANE	80MG/15ML	N87449 001	Sep 15, 1983	Mar	DISC
>A>			@	80MG/15ML	N87449 001	Sep 15, 1983	Mar	DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT	+	ATON		EQ 0.25% BASE	N18086 001		Feb	CAHN
AT	+			EQ 0.5% BASE	N18086 002		Feb	CAHN
			TIMOPTIC IN OCUDOSE					
	+	ATON		EQ 0.25% BASE	N19463 001	Nov 05, 1986	Feb	CAHN
	+			EQ 0.5% BASE	N19463 002	Nov 05, 1986	Feb	CAHN

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB	+	ATON		EQ 0.25% BASE	N20330 001	Nov 04, 1993	Feb	CAHN
AB	+			EQ 0.5% BASE	N20330 002	Nov 04, 1993	Feb	CAHN

TABLET; ORAL

TIMOLOL MALEATE

>D>	AB		MYLAN	5MG	N72666 001	Jun 08, 1990	Mar	CTEC
>A>				5MG	N72666 001	Jun 08, 1990	Mar	CTEC
>D>	AB			10MG	N72667 001	Jun 08, 1990	Mar	CTEC
>A>				10MG	N72667 001	Jun 08, 1990	Mar	CTEC
>D>	AB	+		20MG	N72668 001	Jun 08, 1990	Mar	CTEC
>A>		+		20MG	N72668 001	Jun 08, 1990	Mar	CTEC
>D>	AB		SANDOZ	5MG	N72550 001	Apr 13, 1989	Mar	DISC
>A>			@	5MG	N72550 001	Apr 13, 1989	Mar	DISC

TABLET; ORAL

TIMOLOL MALEATE

>D>	AB	SANDOZ	10MG	N72551 001	Apr 13, 1989	Mar	DISC
>A>		@	10MG	N72551 001	Apr 13, 1989	Mar	DISC
>D>	AB		20MG	N72552 001	Apr 13, 1989	Mar	DISC
>A>		@	20MG	N72552 001	Apr 13, 1989	Mar	DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

>D>	AB	IVAX PHARMS	100MG	N18894 001	Nov 02, 1984	Mar	CTEC
>A>			100MG	N18894 001	Nov 02, 1984	Mar	CTEC
>D>	AB	SANDOZ	100MG	N71633 001	Dec 09, 1987	Mar	DISC
>A>		@	100MG	N71633 001	Dec 09, 1987	Mar	DISC
>D>	AB		250MG	N70289 001	Mar 13, 1986	Mar	DISC
>A>		@	250MG	N70289 001	Mar 13, 1986	Mar	DISC
>D>	AB		500MG	N70290 001	Mar 13, 1986	Mar	DISC
>A>		@	500MG	N70290 001	Mar 13, 1986	Mar	DISC

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

>D>	AB	SANDOZ	500MG	N86574 001		Mar	DISC
>A>		@	500MG	N86574 001		Mar	DISC

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

>D>	AB	SANDOZ	EQ 200MG BASE	N73588 001	Jul 31, 1992	Mar	DISC
>A>		@	EQ 200MG BASE	N73588 001	Jul 31, 1992	Mar	DISC
>D>	AB		EQ 600MG BASE	N74002 001	Sep 27, 1993	Mar	DISC
>A>		@	EQ 600MG BASE	N74002 001	Sep 27, 1993	Mar	DISC

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

>A>	AB	ORTHO MCNEIL JANSSEN	15MG	N20844 001	Oct 26, 1998	Mar	CFTG
>A>	AB	+	25MG	N20844 002	Oct 26, 1998	Mar	CFTG
		TOPAMAX SPRINKLE					
>D>		ORTHO MCNEIL JANSSEN	15MG	N20844 001	Oct 26, 1998	Mar	CFTG
>D>		+	25MG	N20844 002	Oct 26, 1998	Mar	CFTG
		TOPIRAMATE					
>A>	AB	BARR	15MG	N76448 001	Apr 15, 2009	Mar	NEWA
>A>	AB		25MG	N76448 002	Apr 15, 2009	Mar	NEWA
>A>	AB	COBALT LABS INC	15MG	N77868 001	Apr 15, 2009	Mar	NEWA
>A>	AB		25MG	N77868 002	Apr 15, 2009	Mar	NEWA
>A>	AB	TEVA	15MG	N76575 001	Apr 17, 2009	Mar	NEWA
>A>	AB		25MG	N76575 002	Apr 17, 2009	Mar	NEWA

TABLET; ORAL

TOPAMAX

>D>		+	ORTHO MCNEIL JANSSEN	25MG	N20505 004	Dec 24, 1996	Mar	CFTG
>A>	AB	+		25MG	N20505 004	Dec 24, 1996	Mar	CFTG
>D>				50MG	N20505 005	Dec 24, 1996	Mar	CFTG
>A>	AB			50MG	N20505 005	Dec 24, 1996	Mar	CFTG
>D>				100MG	N20505 001	Dec 24, 1996	Mar	CFTG
>A>	AB			100MG	N20505 001	Dec 24, 1996	Mar	CFTG

TABLET; ORAL

TOPAMAX

>D>		ORTHO MCNEIL JANSSEN	200MG	N20505 002	Dec 24, 1996	Mar	CFTG
>A>	AB		200MG	N20505 002	Dec 24, 1996	Mar	CFTG

TOPIRAMATE

>A>	AB	APOTEX INC	25MG	N77733 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N77733 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N77733 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N77733 004	Mar 27, 2009	Mar	NEWA
>A>	AB	AUROBINDO PHARMA	25MG	N78462 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N78462 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N78462 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N78462 004	Mar 27, 2009	Mar	NEWA
>A>	AB	BARR	25MG	N76315 001	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76315 002	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76315 003	Mar 27, 2009	Mar	NEWA
>A>	AB	CIPLA LTD	25MG	N76343 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N76343 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76343 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76343 004	Mar 27, 2009	Mar	NEWA
>A>	AB	COBALT LABS INC	25MG	N77643 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N77643 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N77643 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N77643 004	Mar 27, 2009	Mar	NEWA
>A>	AB	GLENMARK GENERICS	25MG	N77627 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N77627 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N77627 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N77627 004	Mar 27, 2009	Mar	NEWA
>A>	AB	INVAGEN PHARMS	25MG	N79162 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N79162 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N79162 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N79162 004	Mar 27, 2009	Mar	NEWA
>A>	AB	MYLAN	25MG	N76314 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N76314 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76314 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76314 004	Mar 27, 2009	Mar	NEWA
>A>	AB	PAR PHARM	25MG	N76311 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N76311 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76311 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76311 004	Mar 27, 2009	Mar	NEWA
>A>	AB	PLIVA HRVATSKA DOO	25MG	N77905 001	Mar 30, 2009	Mar	NEWA
>A>	AB		50MG	N77905 002	Mar 30, 2009	Mar	NEWA
>A>	AB		100MG	N77905 003	Mar 30, 2009	Mar	NEWA
>A>	AB		200MG	N77905 004	Mar 30, 2009	Mar	NEWA
>A>	AB	RANBAXY	25MG	N76327 001	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76327 002	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76327 003	Mar 27, 2009	Mar	NEWA
>A>	AB	ROXANE	25MG	N76306 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N76306 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76306 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76306 004	Mar 27, 2009	Mar	NEWA
>A>	AB	SUN PHARM INDS LTD	25MG	N90278 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N90278 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N90278 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N90278 004	Mar 27, 2009	Mar	NEWA
>A>	AB	TEVA	25MG	N76317 001	Mar 27, 2009	Mar	NEWA

TABLET; ORAL

TOPIRAMATE

>A>	AB	TEVA	50MG	N76317 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N76317 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N76317 004	Mar 27, 2009	Mar	NEWA
>A>	AB	TORRENT PHARMS	25MG	N79153 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N79153 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N79153 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N79153 004	Mar 27, 2009	Mar	NEWA
>A>	AB	UNICHEM	25MG	N90162 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N90162 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N90162 003	Mar 27, 2009	Mar	NEWA
>A>	AB	ZYDUS PHARMS USA INC	25MG	N78235 001	Mar 27, 2009	Mar	NEWA
>A>	AB		50MG	N78235 002	Mar 27, 2009	Mar	NEWA
>A>	AB		100MG	N78235 003	Mar 27, 2009	Mar	NEWA
>A>	AB		200MG	N78235 004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB		HETERO DRUGS	5MG	N79234 001	Jan 27, 2009	Jan	NEWA
AB			10MG	N79234 002	Jan 27, 2009	Jan	NEWA
AB			20MG	N79234 003	Jan 27, 2009	Jan	NEWA
AB			100MG	N79234 004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

>D>	BC	+	LABOPHARM CANADA INC	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
>D>	BC			200MG	N21745 002	Dec 30, 2008	Mar	CAHN
>D>	BC			300MG	N21745 003	Dec 30, 2008	Mar	CAHN
>A>	BC	+	PURDUE PHARMA	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
>A>	BC			200MG	N21745 002	Dec 30, 2008	Mar	CAHN
>A>	BC			300MG	N21745 003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

>D>		@	BIOVAIL	50MG	N21693 001	May 05, 2005	Mar	CAHN
>A>		@	ETHYPHARM NORTH	50MG	N21693 001	May 05, 2005	Mar	CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB		ALVOGEN	50MG	N71636 001	Apr 18, 1988	Feb	CAHN	
AB			100MG	N71514 001	Apr 18, 1988	Feb	CAHN	
>D>	AB		SANDOZ	50MG	N72484 001	Apr 30, 1990	Mar	DISC
>A>		@		50MG	N72484 001	Apr 30, 1990	Mar	DISC
>D>	AB			100MG	N72483 001	Apr 30, 1990	Mar	DISC
>A>		@		100MG	N72483 001	Apr 30, 1990	Mar	DISC

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

>A>		+	ENDO PHARMS	60MG	N22103 001	Aug 03, 2007	Mar	CAHN
>D>		+	INDEVUS	60MG	N22103 001	Aug 03, 2007	Mar	CAHN

TABLET; ORAL

SANCTURA

>A>	+	ENDO PHARMS	20MG	N21595 001	May 28, 2004	Mar	CAHN
>D>	+	INDEVUS	20MG	N21595 001	May 28, 2004	Mar	CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

	+	DORC	0.15%	N22278 001	Feb 20, 2009	Feb	NEWA
--	---	------	-------	------------	--------------	-----	------

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

>A>	+	ENDO PHARMS	40MG/ML	N20892 001	Sep 25, 1998	Mar	CAHN
>D>	+	INDEVUS PHARMS	40MG/ML	N20892 001	Sep 25, 1998	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

>D>	AB	SANDOZ	40MG	N73168 001	Jul 31, 1992	Mar	DISC
>A>		@	40MG	N73168 001	Jul 31, 1992	Mar	DISC
>D>	AB		80MG	N71423 001	May 24, 1988	Mar	DISC
>A>		@	80MG	N71423 001	May 24, 1988	Mar	DISC
>D>	AB		120MG	N71424 001	May 25, 1988	Mar	DISC
>A>		@	120MG	N71424 001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

>A>		TABLET; SUBLINGUAL					
>A>		EDLUAR					
>A>		OREXO AB	5MG	N21997 001	Mar 13, 2009	Mar	NEWA
>A>	+		10MG	N21997 002	Mar 13, 2009	Mar	NEWA

OTC DRUG PRODUCT LIST - 29TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

>D>	COREPHARMA	650MG	N76200 001	Mar 19, 2002	Mar	CAHN
>A>	OHM LABS	650MG	N76200 001	Mar 19, 2002	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	DR REDDYS LABS LTD	5MG/5ML	N90474 002	Mar 30, 2009	Mar	NEWA
>A>	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
>A>	DR REDDYS LABS LTD	5MG/5ML	N90474 001	Mar 30, 2009	Mar	NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	ORCHID HLTHCARE	5MG	N78862 001	Feb 19, 2009	Feb	NEWA
		10MG	N78862 002	Feb 19, 2009	Feb	NEWA

CETIRIZINE HYDROCHLORIDE HIVES

	ORCHID HLTHCARE	5MG	N78862 003	Feb 19, 2009	Feb	NEWA
		10MG	N78862 004	Feb 19, 2009	Feb	NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+	RECKITT BENCKISER	EQ 30MG HBR/5ML	N18658 001	Oct 08, 1982	Feb	CAHN
---	-------------------	-----------------	------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

>A>	BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	N78682 001	Mar 24, 2009	Mar	NEWA
	MIDOL LIQUID GELS					
+	BANNER PHARMACAPS	200MG	N21472 001	Oct 18, 2002	Feb	CTNA

TABLET; ORAL

IBUPROFEN

>D>	SANDOZ	200MG	N70733 001	Sep 19, 1986	Mar	DISC
>A>	@	200MG	N70733 001	Sep 19, 1986	Mar	DISC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

@	LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	Apr 29, 1992	Jan	DISC
---	-------	-------------------------	------------	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	IVAX PHARMS	EQ 2MG BASE	N76880 001	Feb 18, 2009	Feb	NEWA
		EQ 4MG BASE	N77850 001	Feb 18, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

>D>	SANDOZ	EQ 75MG BASE	N75519 001	Sep 26, 2002	Mar	DISC
>A>	@	EQ 75MG BASE	N75519 001	Sep 26, 2002	Mar	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2009

NO MARCH 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
022320 001	>A> 4717720	May 31, 2010	DS DP			
	>A> RE34440	May 31, 2010			U-818	
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
020983 001	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	>A> 6431168	Jun 08, 2018	DP			
	>A> 6431168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 06, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 001	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 002	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 003	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 004	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 005	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 006	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 007	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 008	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 009	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 010	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 011	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010			U-452	
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008		DP		
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008		DP		
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008		DP		
	5433959*PED	Mar 03, 2009				
<u>ANASTROZOLE - ARIMIDEX</u>						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
<u>ARMODAFINIL - NUVIGIL</u>						
021875 002					>A> NP	Jun 15, 2010
<u>ARMODAFINIL - NUVIGIL</u>						
021875 005					>A> NP	Jun 15, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 001	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 002	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 003	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 004	>A> RE40667	Dec 28, 2010	DS DP U-162			
	>A> RE40667*PED	Jun 28, 2011				
<u>AZITHROMYCIN - AZASITE</u>						
050810 001	5192535	Mar 09, 2010	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
050819 001	5733886	Mar 31, 2015	DP U-124			
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
050741 001	5466446	Feb 16, 2014	DS DP			
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	May 24, 2017	DP			
<u>BIMATOPROST - LATISSE</u>						
022369 001					NP	Dec 24, 2011
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
050786 001	>A> 5196205	Mar 23, 2010	U-933			
	>A> 5476669	Mar 23, 2010	U-933			
	>A> 6350468	Dec 14, 2018	U-956			
	>A> 6350468	Dec 14, 2018	U-932			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 001					I-582	Feb 27, 2012
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 002					I-582	Feb 27, 2012
<u>CALCITRIOL - VECTICAL</u>						
022087 001					NDF	Jan 23, 2012
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CICLESONIDE - ALVESCO</u>						
021658 002					NDF NCE	Jan 10, 2011 Oct 20, 2011
<u>CICLESONIDE - ALVESCO</u>						
021658 003					NDF NCE	Jan 10, 2011 Oct 20, 2011
<u>CLARITHROMYCIN - BIAXIN XL</u>						
050775 001	>A> 6551616	Jul 15, 2017	U-924			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
021142 001	6126920	Mar 01, 2016	U-484			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021176 001	5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
	5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-323			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-851			
	7229613*PED	Oct 17, 2022				
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 001	5925730	Apr 11, 2017	DS DP U-943			
<u>DEGARELIX ACETATE - DEGARELIX ACETATE</u>						
022201 002	5925730	Apr 11, 2017	DS DP U-943			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
050818 001	5149694	Sep 22, 2009	U-953			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
020062 005	>A> 5286497	May 20, 2011	DP			
	>A> 5439689	Aug 08, 2012	DP U-107			
	>A> 5470584	May 20, 2011	DP			
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
077567 002					PC	Aug 01, 2009
<u>DOXERCALCIFEROL - HECTOROL</u>						
021027 001	>A> 5707980	Aug 17, 2010	U-321	Y		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 001					>A> NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 002					>A> NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 003					>A> NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021365 001					>A> NPP	Mar 19, 2012
<u>ESTRADIOL - ELESTRIN</u>						
021813 001	7470433	Aug 03, 2021	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 001	>A> 5665772	Sep 09, 2014	DS DP		>A> NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP			
	>A> 7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 002	>A> 5665772	Sep 09, 2014	DS DP		>A> NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP			
	>A> 7297703	Dec 06, 2019	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE</u>						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 001	>A> 6960577	Nov 01, 2017	U-963		>A> I-590 >A> I-589	Mar 19, 2012 Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 003	>A> 6960577	Nov 01, 2017	U-963		>A> I-590 >A> I-589	Mar 19, 2012 Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 006	>A> 6960577	Nov 01, 2017	U-963		>A> I-590 >A> I-589	Mar 19, 2012 Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 001	>A> 6960577	Nov 01, 2017	U-962		>A> I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 002	>A> 6960577	Nov 01, 2017	U-962		>A> I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 003	>A> 6960577	Nov 01, 2017	U-962		>A> I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 004	>A> 6960577	Nov 01, 2017	U-962		>A> I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 005	>A> 6960577	Nov 01, 2017	U-962		>A> I-593	Mar 19, 2012
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
>A>	6161724	Jan 16, 2018	DP			
>A>	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
>A>	6431168	Jun 08, 2018	DP			
>A>	6431168*PED	Dec 08, 2018				
>A>	6435372	Jan 16, 2018	DP			
>A>	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
>A>	6596260	Aug 10, 2014	DP			
>A>	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
>A>	6938796	Jan 16, 2018	DP			
>A>	6938796*PED	Jul 16, 2018				
>A>	6966467	Dec 23, 2017	DP			
>A>	6966467*PED	Jun 23, 2018				
>A>	6997349	Jan 16, 2018	DP			
>A>	6997349*PED	Jul 16, 2018				
>A>	7107986	Jun 08, 2018	DP			
>A>	7107986*PED	Dec 08, 2019				
>A>	7143908	Jan 16, 2018	DP			
>A>	7143908*PED	Jul 16, 2018				
>A>	7350676	Aug 24, 2018	DP			
>A>	7350676*PED	Feb 24, 2019				
>A>	7500444	Jan 04, 2025	DP			
>A>	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
>A>	6161724	Jan 16, 2018	DP			
>A>	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
>A>	6431168	Jun 08, 2018	DP			
>A>	6431168*PED	Dec 08, 2018				
>A>	6435372	Jan 16, 2018	DP			
>A>	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
>A>	6596260	Aug 10, 2014	DP			
>A>	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
>A>	6938796	Jan 16, 2018	DP			
>A>	6938796*PED	Jul 16, 2018				
>A>	6966467	Dec 23, 2017	DP			
>A>	6966467*PED	Jun 23, 2018				
>A>	6997349	Jan 16, 2018	DP			
>A>	6997349*PED	Jul 16, 2018				
>A>	7107986	Jun 08, 2018	DP			
>A>	7107986*PED	Dec 08, 2019				
>A>	7143908	Jan 16, 2018	DP			
>A>	7143908*PED	Jul 16, 2018				
>A>	7350676	Aug 24, 2018	DP			
>A>	7350676*PED	Feb 24, 2019				
>A>	7500444	Jan 04, 2025	DP			
>A>	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
>A>	6161724	Jan 16, 2018	DP			
>A>	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
>A>	6431168	Jun 08, 2018	DP			
>A>	6431168*PED	Dec 08, 2018				
>A>	6435372	Jan 16, 2018	DP			
>A>	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
>A>	6596260	Aug 10, 2014	DP			
>A>	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
>A>	6938796	Jan 16, 2018	DP			
>A>	6938796*PED	Jul 16, 2018				
>A>	6966467	Dec 23, 2017	DP			
>A>	6966467*PED	Jun 23, 2018				
>A>	6997349	Jan 16, 2018	DP			
>A>	6997349*PED	Jul 16, 2018				
>A>	7107986	Jun 08, 2018	DP			
>A>	7107986*PED	Dec 08, 2019				
>A>	7143908	Jan 16, 2018	DP			
>A>	7143908*PED	Jul 16, 2018				
>A>	7350676	Aug 24, 2018	DP			
>A>	7350676*PED	Feb 24, 2019				
>A>	7500444	Jan 04, 2025	DP			
>A>	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	5590645	Mar 01, 2011	DP		>A> M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	5590645	Mar 01, 2011	DP		>A> M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	5590645	Mar 01, 2011	DP		>A> M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 001	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015				U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP			U-738
	6253762*PED	Oct 14, 2015				U-738
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	>A> 6161724	Jan 16, 2018	DP			
	>A> 6161724*PED	Jul 16, 2018				
	>A> 6170717	Dec 23, 2017	DP			
	>A> 6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	>A> 6341168	Jun 08, 2018	DP			
	>A> 6341168*PED	Dec 08, 2018				
	>A> 6435372	Jan 16, 2018	DP			
	>A> 6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	>A> 6596260	Aug 10, 2014	DP			
	>A> 6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	>A> 6938796	Jan 16, 2018	DP			
	>A> 6938796*PED	Jul 16, 2018				
	>A> 6966467	Dec 23, 2017	DP			
	>A> 6966467*PED	Jun 23, 2018				
	>A> 6997349	Jan 16, 2018	DP			
	>A> 6997349*PED	Jul 16, 2018				
	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
	>A> 7143908	Jan 16, 2018	DP			
	>A> 7143908*PED	Jul 16, 2018				
	>A> 7350676	Aug 24, 2018	DP			
	>A> 7350676*PED	Feb 24, 2019				
	>A> 7500444	Jan 04, 2025	DP			
	>A> 7500444*PED	Jul 04, 2025				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 001					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 002					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 003					M-83	Apr 14, 2011
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADODIAMIDE - OMNISCAN</u>						
022066 002	5362475	Nov 08, 2011	DS			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 001					>A> I-594	Feb 27, 2012
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 002					>A> I-594	Feb 27, 2012
<u>GOSERELIN ACETATE - ZOLADEX</u>						
019726 001	>A> 7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
020578 001	>A> 7500964	Feb 26, 2021	DP			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001					I-583	Dec 19, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002					I-583	Dec 19, 2011
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001	5750497	May 16, 2019	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	>A> 7476652	Jul 23, 2023	DP			
	>A> 7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
021629 002					>A> NCE	Apr 16, 2009
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
021629 003					>A> NPP >A> NCE	Oct 24, 2011 Apr 16, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020351 002	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020808 002	RE36418	Jul 12, 2011	DP			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 001	>A> 6605599	May 26, 2018	DS DP U-961			
	>A> 6670384	Jan 23, 2022	DP U-960			
	>A> 6670384	Jan 23, 2022	DP U-959			
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7125899	May 26, 2018	DS DP U-957			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 002	>A> 6605599	May 26, 2018	DS DP U-961			
	>A> 6670384	Jan 23, 2022	DP U-960			
	>A> 6670384	Jan 23, 2022	DP U-959			
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7125899	May 26, 2018	DS DP U-957			
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID IV</u>						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 001	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 002	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Oct 26, 2018	DP U-613			
<u>LEVETIRACETAM - KEPPRA XR</u>						
022285 002					NDF	Sep 12, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
022114 001					NPP	Jan 08, 2012
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 001	>A> 5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 002	>A> 5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021627 001	>A> 5061703	Apr 11, 2015	U-539			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 001	>A> 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 002	>A> 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 003	>A> 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 004	>A> 6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 17, 2021	U-882			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067 002	>A> 5394868	Jun 25, 2012	DP		>A> NPP	Feb 01, 2011
	>A> 5394868*PED	Dec 25, 2012				
	>A> 5687710	Nov 18, 2014	DP			
	>A> 5687710*PED	May 18, 2015				
	>A> 5829434	Nov 03, 2015	DP			
	>A> 5829434*PED	May 03, 2016				
	>A> 5889015	Jan 27, 2014		U-645		
	>A> 5889015*PED	Jul 27, 2014				
	>A> 6057307	Jan 27, 2014	DP	U-645		
	>A> 6057307*PED	Jul 27, 2014				
	>A> 6240918	Feb 20, 2017	DP			
	>A> 6240918*PED	Aug 20, 2017				
	>A> 6365581	Jan 27, 2014		U-645		
	>A> 6365581*PED	Jul 27, 2014				
	>A> 6503537	Mar 17, 2018	DP			
	>A> 6503537*PED	Sep 17, 2018				
	>A> 6677322	Jan 27, 2014		U-645		
	>A> 6677322*PED	Jul 27, 2014				
	>A> 6949532	Jan 27, 2014		U-645		
	>A> 6949532*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
021260 006	6066339	Nov 25, 2017	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
021780 001	5869082	Apr 16, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
020592 001	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 002	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
020592 003	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 004	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 005	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 006	>A> 6960577	Nov 01, 2017	U-963		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 001	>A> 6960577	Nov 01, 2017	U-964		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 002	>A> 6960577	Nov 01, 2017	U-964		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 003	>A> 6960577	Nov 01, 2017	U-964		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 004	>A> 6960577	Nov 01, 2017	U-964		>A> I-592 >A> I-591	Mar 19, 2012 Mar 19, 2012
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
021654 001	>A> 5656667	Apr 10, 2017	DS DP U-822			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
022204 001	>A> 7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	>A> 7179483	Apr 26, 2020	U-318			
<u>PALIPERIDONE - INVEGA</u>						
021999 006	>A> 5158952	Oct 27, 2009	DP U-90			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
022020 001	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 002	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 003	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>RISPERIDONE - RISPERIDONE</u>						
076440 001					PC	Jul 29, 2009
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SILODOSIN - RAPAFLO</u>						
022206 001	>A> 5780485	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
022206 002	>A> 5780485	Nov 13, 2012	U-902			
<u>SINECATECHINS - VEREGEN</u>						
021902 001	>A> 5795911	Oct 31, 2020	U-172			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 001					>A> I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 004	>A> 5612315	Mar 18, 2014	DP		>A> I-585	Mar 12, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 005	>A> 5612315	Mar 18, 2014	DP		>A> I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 006	>A> 5612315	Mar 18, 2014	DP		>A> I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 007	>A> 5612315	Mar 18, 2014	DP		>A> I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 004	>A> 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 005	>A> 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 006	>A> 5849700	Dec 15, 2015	U-340			
	>A> 5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 007	>A> 5849700	Dec 15, 2015	U-340		>A> I-572	Oct 31, 2011
	>A> 5849704	Dec 15, 2015	DP U-340		>A> I-551	Sep 20, 2010
					>A> I-536	May 31, 2010
					>A> ODE	May 31, 2014
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076572 001					PC	Aug 09, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 003					PC	Aug 09, 2009
<u>SUNITINIB MALATE - SUTENT</u>						
021938 004	>A> 6573293	Feb 15, 2021	DS DP U-703		>A> NCE	Jan 26, 2011
	>A> 7125905	Feb 15, 2021	DS DP			
	>A> 7211600	Dec 22, 2020	U-883			
<u>TEMOZOLOMIDE - TEMODAR</u>						
022277 001	>A> 5260291	Aug 11, 2013	DS DP U-619			
	>A> 5260291*PED	Feb 11, 2014				
	>A> 6987108	Sep 08, 2023	DP			
<u>TIGECYCLINE - TYGACIL</u>						
021821 001					>A> I-588	Mar 20, 2012
					>A> I-587	Mar 20, 2012
					>A> I-586	Mar 20, 2012
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 001	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 002	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	>A> 7498311	Oct 13, 2015	U-955			
	>A> 7498311*PED	Apr 13, 2016				
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 001					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 002					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 003					NP	Dec 30, 2011
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
022278 001					NCE	Dec 16, 2009
					>A> ODE	Dec 16, 2011
<u>ZOLEDRONIC ACID - RECLAST</u>						
021817 001					>A> I-584	Mar 15, 2012
					I-581	Dec 19, 2011
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 001	>A> 6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 002	>A> 6761910	Sep 24, 2018	DP U-674			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>